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VENTRICULOPERITONEAL SHUNTS INFECTIONS IN 
PAEDIATRIC PATIENT 
INTRODUCTION  
Ventriculoperitoneal  shunts  are  used  for  maintaining  a  specific  
intracranial  pressure  management  and  temporary  cerebrospinal  fluid  
drainage.  The  placement  and  revision  of  VP  shunts  remain  a  mainstay  in  
the  surgical  treatment  of  hydrocephalus. 
Shunt  infections  constitute  one  of   the  main  risks  of  Ventriculo 
peritoneal shunt surgery,  which   is  the  single  most  common  surgery  
performed  by  paediatric  neurosurgery,  making  up  nearly  half  of  all  cases  
in this  speciality3.  
Shunt  infection  is  suspected  when    at  least  one  of  the  following  
criteria  is present  
1.  The  isolation    of  an  organism   from  CSF  culture.   
2.  The  presence  of  fever  in  the  absence  of  other  recognized  causes,  with  
institution  of  appropriate  antimicrobial  treatment  and;  
3.  Any  one  of  the  following - increased  white  cell  count  (>50%  
polymorphonuclear  leucocytes),  increased  proteins  and  /or   decreased  
glucose  (<  15g/ dl )  in  CSF,  organisms  visible  on  CSF  Gram   stain7. 
CSF  produced  from  major  intraventricular  production  site,  surrounds  
the  brain  and  spinal cord  by  circulating  through  the  ventricles  and  
subarachnoid  space  and  is  later   reabsorbed  in  circulation  by   arachnoid  
villi. 
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Any  interruption  in  secretion,  flow  and  its  absorption   from  major  
production  site  to  terminal  absorption  site  results  in  accumulation  of  fluid.  
Diversionary  devices like  shunts are  important  to  divert  this  excess  fluid  
to  other  body  compartments,  where  it  can  be  removed  naturally2.  This  
provides  a  rapid  means  of  normalizing  intracranial  pressure  and  can  
prevent  neuronal  damage  and  other  detrimental  sequalae,  affecting  the  
milestones  and  intellectual  development  of  the  growing  brain10.   
The  most  common  type  of  shunt  is  the  ventriculo-peritoneal  shunt,  
which  drains  fluid  from  the  ventricles  to  the  abdomen.  Less  common  
types  of  shunt  are;   
 Ventriculo-atrial  shunts 
 Ventriculo- pleural  shunts  
 Ventriculo-gall  bladder  shunts  
This  device  has  three  compartments 
1.  Ventricular catheter  to reach   the  lateral  ventricles  of  brain. 
2.  Valve  to  control  the  flow.                            
3.  Tubing  to  divert  this  excess  fluid  to  peritoneal  site.  
Though Ventriculo –peritoneal  shunt  placement  is  the  main stay  of   
hydrocephalus  treatment,  it is  associated  with  chronic   surgical  and  medical  
problems. Each  revision  is  associated   with  malfunction  and  increases  the  
rate  of  infection. Incidence  of  infection  ranges  from   5-15%.  In case  of  
CSF infections  due  to any  device , it  is associated   with  signs  and  symptoms   
of  acute  bacterial  meningitis4. 
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Infection  if  untreated    causes  developmental  disorders,  mental  
deficiencies  and  shortened  life  expectancy  in addition  to  blindness  and  
other  neurological  deficits  as  a  result  of  cerebral  injury  due  to  distension  
of  brain   tissue8. 
Risk factors  include  chronological  age,  gestational  age ,  
postconceptional  age,  sex,  birth weight ,  weight  at  surgery ,  indication  for  
shunt  placement  including  myelomeningocele  and  intra ventricular  
hemorrhage, trauma , length  of  hospital  stay  and  post-infective pathology 
(Tuberculous Menigitis , Pyogenic meningitis, hydrocephalus  and  sporadic  
cases)11. 
In  patients  undergoing  a  shunt  procedure,  the  infectious   pathogen  
will  most  likely  be  a  microorganism  from  the  resident  bacterial  flora  of  
the  skin,  nasopharynx,  and  external  auditory  canal.  Prolonged   hospital  
stay  is  unavoidable  and  hence  nosocomial  infections , bacterial  coinfections, 
aspiration  of  gastric  contents  in  comatose  patients,  and  use  of  broad  
spectrum  antibiotics  are  to  be  considered.  Shunt pathogens  are  Coagulase  
Negative  Staphylococcus  (65%)  and  Staphylococcus  aureus  which  are  
usually  skin commensals,  followed  by  Gram  Negative  Bacteria  (19- 22%),  
due   to  bacterial  colonization  of  stomach  with aerobes  and  retrograde  
infection  from  peritoneal  site  as  in  case  of  peritonitis4. 
Ventriculoperitoneal  infection  are  classified  into  two  types  based  on  
the  duration.  
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Early Shunt  Infection  -  CSF  infections  within  the  initial  30  days  of  
ventricular  catheter  insertion  were  considered  to  be  early  shunt  infection.  
Causative  pathogens  are  Staphylococcus  aureus and Coagulase negative 
Staphylococcus13. 
Late  Shunt  Infection     -  CSF  infections  which  occur  30  days  after  the  
insertion  were  considered  as  late  shunt  infection.  Causative  pathogens  are  
Gram negative Bacilli (E.coli, Klebsiella, Citrobacter) and Non fermenters 
(Pseudomonas and Acinetobacter)13. 
Prior  Shunt  infections  with  Staphlococcus  aureus  causes  repeated  
shunt  infections,  but  in  case  of  coagulase-negative  Staphylococcus  species  
infection  it is  presumably  not  so. 
Recurrence  of  shunt  infection  ,means  the   isolate  was  different  from  
previous  shunt  infection.  In  Relapse  of  shunt   infection  the  isolate  happens  
to  be  of  the  same  genus  and  species  and occurs  within  one  month  of  
treatment  . A  shunt  revision  was  defined  as  an  operative  neurosurgical  
intervention  to  the  CSF  shunt16. 
Clinical  features  includes  high/intermittent  fever,  seizures,  vomiting  
,increase  in  head  circumference,  abdominal  distension  especially  in  
paediatric  cases  and  a  positive  CSF  analysis  as  described  earlier19.  
Drugs  must  attain  therapeutic  concentration  in  CNS  for  effective  
management.  Oral  drugs  with  high  bioavailability  and  effective  penetration  
of  Blood Brain Barrier  can  be  used  in  children. Duration  of  antibiotics  
administered  is usually  for    3 to  21  days  and  CSF  culture  must  be  negative  
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for  revision  of  VP shunt  surgeries . Broad  spectrum  antibiotics  are  started  
when  signs ,  symptoms as  well  as  CSF  biochemical  and  cytological  reports   
are  supportive  of   Acute  Bacterial  Meningitis  but  culture  is  the   gold  
standard20. Treatment  is  meticously  narrowed  down  based  on  CLSI  
GUIDELINES,  to  prevent   emerging  Antibiotic  Resistance  and  to  avoid  
certain  drugs  to  which    Intrinsic  Resistance  is  geneticaly  transmitted18.   
The  low  pathogenicity    of   some  implicate  pathogens ,  chronological  
age  of  the  patient  ,  non  specific  clinical  signs  and  symptoms  ,  increase  
in  head  size  with  fever   [the   only  symptom  below  2  yrs], older   children   
with  triad   of  headache,  vomiting   and  papilloedema  make  the  diagnosis  
of  infection   in  intact  shunt  cumbersome. Development   of   shunt  surgeries  
has  remarkably  changed  the  outcome  in  these  patients  with  vulnerable  
age  group  to  lead  a  normal  life20.    
VP  shunt  infection  is an important  devastating  complication of shunt 
surgery, associated   with  high  morbidity and mortality. In  the  recent  years  
the  organisms  associated  with  these  infections  are   multi drug resistant. 
Hence  early  and  prompt  diagnosis  of   Ventriculoperitoneal  shunt infection  
is  crucial. The  study  helps  to formulate  effective  antibiotic  policy  for  a  
better  clinical  outcome  thereby giving  a chance  to lead  a near  normal  life  
for  these  patients22. 
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AIM AND OBJECTIVES 
 
AIM: 
To analyse risk factors, microbiological, microbial profile, antibiotic sensitivity 
and clinical outcome of Ventriculoperitoneal shunt infections in paediatric 
patients. 
 
 
OBJECTIVES: 
 Analysis of risk factors for developing infections. 
 Isolation and identification of pathogens involved. 
 To identify  resistance pattern among culture positive isolates by  
antibiotic sensitivity tests. 
 Assessment of clinical outcome of post operative VP shunt surgery. 
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REVIEW OF LITERATURE 
1. CDC 2018 guidelines  has  provided  reporting  instructions  for   CSF  
shunt  infection  as  SSI-MEN (surgical   site  infection  - meningitis  and  
encephalitis)  when  infection  occurs  within  90 days  of  placement,  
and  if  infection  occurs  beyond  90  days  of  placement  its  reported  
as CNS-MEN ( Central  Nervous  System- meningitis   and  
encephalitis)14. 
2. In  case  of  meningitis (MEN)  and  encephalitis  (IC)  present  together,  
it  has  to  be  reported  as MEN.  
3. In  case  of  meningitis (MEN)and  brain  abscess  (IC)present  together,  
it  has  to be  reported  as IC  and  SA if meningitis (MEN) and spinal 
abscess (SA) are present together.  
 The  principle  of  ventriculoperitoneal  shunts  is  to  drain  excess   of 
accumulated  cerebrospinal  fluid  into  the  peritoneal  cavity in case of 
hydrocephalus thus relieving   the  pressure  in  the  brain.  Development  of  
brain  is crucial  during  the  first  two  years  of  life, and an   indication  for  
ventriculoperitoneal  surgery  during  this  age  group  has  both  faces  of  a  
coin. This  common  entity  in  neurology  targets  the  normal   hydrodynamics 
of  cerebrospinal  fluid   surrounding  the  brain  and  spinalcord16. 
 Hydrocephalus  is due  to congenital   obstruction  as in  case  of    
aqueduct  of  Sylvius, congenital malformation  like  Arnold  - Chiari  and  
Dandy-Walker  malformation  and  neural  tube  defects for which 
Ventriculoperitoneal  shunt  insertion  is  the  treatment  of  choice  It  has  
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improved   and  restored   the   cognitive   and   postural  equilibrium   functions   
in  case  of   posterior  cerebellar  tumours. Remarkable  increase  in   survival  
rate   has   increase  in  post traumatic hydrocephalus  with  subarachnoid  
haemmorhage  and  tuberculous  meningitis23. 
 This meticuolous  surgery  increases  the   survival  and  improves  the  
cognitive  memory  so that   the   patient  in  future  can  lead  an independent  
life but  it’s  drawbacks  vary  from  life  threatening   infection   to  mechanical  
and   biological    malfunction. 
 
HISTORICAL  REVIEW17,18,26 
(1621-1675 )  The  understanding of   ventricular  system  and  CSF  pathway  
was  initiated   by  Thomas  Willis. 
(1876) Key and Retzeus  established  the  modern  concept  of CSF  circulation. 
1881,  Carl  Wernicke performed the  first  sterile  ventricular  puncture  and  
external  ventricular  drain  . 
1903, Nicholas  Senn  performed  first  recorded  surgery  using  perforated  
rubber  tube, a crude  predecessor  of  the  modern  ventriculo peritoneal  shunt. 
1952 , Nulsen  and  Spitz  used  rubber  shunts  to  divert  CSF,  John  Holter  
replaced  rubber  shunts  by  silicone  shunts  and  this  was   used   for  his  
hydrocephalic  son  successfully. 
1960, Ransohoff  et  al  proved  success  rate  of  65%  with  Ventriculo  
Peritoneal  infections. 
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1970 ,   peritoneal  cavity  as  best  site  for  CSF  diversion was  proved  by  
Ames  work.  
1908   first  VP shunt  surgery  was  done   by  Cushing, but  it  was  instrumental  
after Scarff’s  meticuolous  work  of  treating hydrocephalus by  
ventriculoperitoneal  shunts  successfully  among  55%  of  230  patients.  
 
SIGNIFICANCE OF VENTRICULOPERITONEAL  SURGERY27,31,52,53 
 To  reduce  abnormal  intracranial  pressure. 
 To  arrest  abnormal  activation  of  inflammatory  cytokines  in  brain  
parenchyma. 
This  diligent  intervention  of  ventriculoperitoneal   shunt  in  
hydrocephalus  is the  treatment  of  choice,  because  this   challenges  both  
cognitive  and  developmental  milestones   among   children. 
  
10 
 
INCLUSION  CRITERIA  FOR  VENTRICULOPERITONEAL  SHUNT  
INFECTION 
Shunt  infection  includes  both  meningitis   and  encephalitis  and  must  
satisfy   following   criteria; 
1) The  isolation    of  an  organism   from  CSF  culture  or  non  culture  
methods 
 
  
2)    Any  two  clinical  signs  
1. AGE ≥ 1 YEAR 2. AGE ≤ 1 YEAR 
3. Fever  or  headache 4. Fever, hypothermia,  apnea, 
bradycardia, irritability 
5. Meningeal  signs  6. Meningeal  signs   
7. Cranial  signs 8. Cranial  nerve  signs 
 
3 Any  one   of  the  supporting   documents 
a)   Increase  WBC , elevated  protein  ,and   decreased  glucose  in  CSF 
b)   Organism   visible   on  Gram  stain 
c)   Organism   isolated   from  blood    by  culture  and  non  culture  
methods 
d) Diagnostic  single  antibody   titre (Ig M)  or  four  fold   increase  in  
paired   sera  (IgG )  for  organisms. 
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INDICATIONS OF  INFECTION FOLLOWING 
VENTRICULOPERITONEAL  SHUNT  SURGERY.  
1) DIAGNOSTIC   INDICATIONS  
 Suspected  cases  with  signs  and  symptoms of shunt  infection . 
 Communicating  or  Obstructive  hydrocephalus.   
 Signs  in  favour  of  acute  bacterial  meningitis. 
 Signs  indicating  posterior  fossa  tumours. 
 Congenital  causes  Meningomyelocele  with  Arnold  Chiari  
malformations. 
 Post – meningitic  hydrocephalus 
 Signs   suggesting  CSF leakage  or  pseudo meningocele. 
 
THERAPEUTIC  INDICATIONS32 
 Malfunction  of  ventriculoperitoneal  shunt  device. 
CONTRAINDICATIONS 
Absolute  contraindication  include  infection  over  the  entry  site 
especially when  CSF culture  from   Extra   Ventricular  Drain  is  positive 
 
TYPES  OF  VENTRICULOPERITONEAL  INFECTION33 
Early  onset  ventriculoperitoneal  infection  (SSI-MEN) –   (within  90  days 
of  surgical  procedure).  The  predominant  causative  pathogen   are  Gram 
Positive  Bacteria  associated  with  increased  hospital  stay. 
12 
 
Late  onset  ventriculoperitoneal   infection  (CNS-MEN) -    (after  90  days  
of  Surgical  procedure).  The  predominant  causative  pathogens  are  Gram  
Negative  Bacteria  associated  with  multi  drug  resistance. 
Variations  in   onset   of  shunt  infection  &  infection  rate34 
In  a  study  conducted  by  Nebraska  university, USA,  reported   that  
90% of  infection   occurred   during   first   30   days,   with  incidence   of    
infection   rate  from   10  to  20%. 
International  Surgery   Journal  published  in  May  2017  highlights   
late  infection. This  study  was  conducted  from  2013  to  2016  with  198  
patients, 23  patients  had  shunt  complications  within  30  days  of  shunt  
surgery  and   45  patients  had  shunt  complications  within  a  period  of  5  
months   
 
EPIDEMOLOGY-  global  burden35    
Nearly  200,000  cases  occur  each  year  throughout the  world  and  
12,000cases  of  congenital  hydrocephalus in India  are  reported   and  awaiting   
treatment  by  Ventriculoperitoneal  shunt  surgery. 
The  prevalence  of  hydrocephalus  in  United  States  is 0.5% ; Down  
Syndrome  shares  the   same  prevalence  as  congenital   hydrocephalus. This  
neurosurgical  condition  treatable  by  ventriculoperitoeal shunt  is  more  
common  than   spinabifida  and CNS  tumours  in  USA36. 
In  United  States  shunt  infections   account  for  2,400  admissions  and  
59,000  hospital  days   each  year  despite  aggressive  treatment  as  documented  
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by  HCRN (Hydrocephalus  Clinical  Research  Network)  The   ratio   of   shunt   
revisions   to  primary  shunt   placements   remain  3: 1  at   many   health   care  
centres 
In  India  the  incidence  of  congenital  hydrocephalus  is  about( 0.2–
0.5 /1000 ) live  births  according  to  a  study  by    Advanced  Neuroscience  
Institute,  India. 
In  India,  a  recent  outcome   analysis   of   ventriculoperitoneal  shunt   
surgery   in  paediatric   hydrocephalus  from   April   to  June  2018  done  at  
Ashish  Hospital    and  Research   Institute,  Madhya  Pradesh,  shows  the  
incidence  of   overall  shunt   complications   to  be  35,76%. Shunt   revision   
accounts   for   27%,  shunt  blocade 45.94% ,shunt  infection   was  16.21%   
and   shunt   migration   was  10.81%37. 
Prospective   study  to  formulate   a strategy  to  prevent   infections was  
done   among  486   cases   admitted   during     the   period   from    2006   to   
2013    in  the  Institute   of   Neurology, Madras  Medical   College38.  In  
accordance   with   other   studies  where   infection  rate  was  3.8  to  27%,  the   
Institute   documented   5.4% as  infection  rate .Multiple   revisions   in  this   
study   are   associated   with   infection  rate   ranging   from  5.4%   to  14.28%.   
one  of  the  reason   for  multiple  revisions  are  associated  with  increased  
cellular  content  of  CSF seen  in  post  tuberculous  meningitis39. 
ISK   FACTORS 40,41 
Dr.Simon's studies  has   postulated   the    risk  factors   for   surgeries  
in  his   publication   which   was   supported   by  PCMC   innovative   research   
14 
 
grant. In   his    retrospective   cohort   study of  children   from  0  to  18  years  
on    association   of   intraventricular   hemorrhage   secondary   to  prematurity,  
he  has   enumerated   the  following  as risk  factors: 
 
1) PATIENT  FACTORS   
 Sex  of  the  baby       -    (male   preponderance) 
 Low  Birth  Weight  babies 
 Preterm  babies 
 Age  of  the  baby 
 Weight  of  baby  at  the   time   of  surgery.   
 LOS   preceding    shunt    surgeries  
Patient   factors  are   related    to  immaturity   of  the   neonatal   immune  
system,  poor   skin   barrier   protection  ,  and   altered   skin   bacterial   density   
according    to  studies  by Pople,  Bayston   and  Hayward50. 
2)  SURGEON  FACTORS 
 Experience    of   neuro  surgeon 
 Use   of   neuroendoscope. 
3)  MEDICAL  DECISIONS    
 Use  of  prophylactic  IV  antibiotics    
 Use   of  prophylacticintrathecal   antibiotic  use. 
4) SURGICAL   DECISIONS 
 Shunt  valve  brand   
 Antibiotic   impregnated   shunt   tubing 
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 Distal  shunt  location 
 Case   priority 
 Case  duration 
 
IMMUNOPATHOGENESIS : 
MISINTERPRETATION   OF  DEFENCES  IN  THE  CNS  -   
Infection  of   CNS  is   recognized   by   microglia    and   astrocytes. 
Microglia   activation  after    identifying   the  pathogen  results   in   secretion    
of  TNF –α ,  IL  - 1 β , nitric  oxide   and  super oxide  free  radicals,   thus   
displaying    bactericidal  activity   against   parenchymal   brain  infection30.31,32. 
Microglial   production  of   IL-10   is  neuro  protective  and   strengthens 
neuronal   synapse   formation.  These   unique  protective   factors  are   
harvested   as   therapeutic  targets   to  narrow  down  the   infection.  Astrocytes   
show   protective   effect   by   expressing    pattern  recognition   receptors    and  
produce   chemokines  and   cytokines   in   response   to   infectious   stimuli . 
Normal  CNS  homeostatic  functions   are  maintained   by  Astrocytes  against    
both  Gram  Negative  Citrobacter  meningitis   and  Staphylococcus   aureus   
parenchymal   CNS infection. Astrocytes prevent infection   by  their   control   
of   gap  junction   communications  and  production  of   proinflammatory  
mediators42. 
 Inflammation    of   brain  parenchymal    cells  and  misinterpretation  
against  host  cell  mediated   immunity   results   in  IQ  loss  and   increased   
risk  of  seizures   in  CNS  infections43. 
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DEVICE   ASSOCIATED   INFECTIONS   
SHUNT  HARDWARE  INFECTIONS  
External   shunt   infections    constitute    only   5%  of   shunt   infections  
Internal   shunt   infections   are  due  to  colonization   of  the  inner  surfaces    
of   the   shunt   tubing   and  valve.  The  organism   exist   in  biofilm  state  
raising   its  minimal   inhibitory  concentration   500  times   more  than  in vitro  
sensitivity  result44. 
IDSA  International  Disease  Society  of  America   recommends    
removal  of  the  device   followed   by   Extra Ventricular  Drain45.  Sterility   
of  CSF  is   required    before   insertion   of   new   shunt   to  prevent   recurrence   
of  infection  with  standard   protocol . 
BIOFILMS 
Phenol  soluble  molecules  (PSN)  molecules   have   a   role   in   structure   
and   development   of   biofilms.  These   molecules   lyse  WBC    and  RBC,  
and  thereby   inhibit   immune  function.  They   are  produced   by   staphyloccal    
strains  . 
Staphyloccal  species   has  a  wide  range   of  toxins   which   disrupts   
innate   immune   system  affecting   leukocidin  A  and  B. This   is   sufficient   
to  kill   macrophages,  dendritic  cells   and   neutrophils  . Pore   forming   
toxins   are  Alpha- toxin   and  Valentine  leukocidin   (PVL)   which   have   
been   reported  in  community   acquired   methicillin   resistant   strains46. 
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PARTS   OF  VP  SHUNT    
  INFLOW  CATHETER – VENTRICULAR    CATHETER 
This    portion  of  VP  Shunt   drains  the  CSF  from  the  ventricles  or  sub 
arachnoid  space  and    leaves  the  brain  through  a  small  hole  in  the  Skull,  
which  then   runs  under  the  skin47.  
 
 VALVE  MECHANISM 
 Value  mechanism   regulates  the  differential  pressure   or  controls  the  
flow  through  the  shunt  tubing. This  portion  serves   to  connect   the  inflow  
catheter that  lies  between  the  skin  and  the  skull,  usually  behind  the  ear. 
 Different  types  of  value  mechanism  are; 
• Fixed  differential  pressure   valves 
• Fixed  differential  pressure  valves  with  an  antisiphon  mechanism 
• Programmable  differential  valves -  most  preferred  valves 
• Programmable  differential  valves  with  an  antisiphon  mechanism 
 
 OUT FLOW  CATHETER -  DISTAL   CATHETER 
This  runs  under  the  skin  and  directs  CSF  from  the  valve  to  the  abdominal  
cavity . Minimal  access  to  infection  because  its   the   longest  and largest  
component  of  ventriculo  peritoneal  shunt.  Barium  Impregnation  allows  
radiographic  visualization  of  accurate  anatomical   position  of  outflow  
catheter48. 
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Different  types  of  VP  Shunt49 
1) Spitz  -Holter   valve   -  unidirectional    valve   currently  used  in  tertiary  
care  units. 
2) Ommaya  valves  with   reservoirs    to  allow   easy   access  for  ventricular   
sampling    and   easy   access    of  drugs . 
3) Inbuilt   pressure   sensing   valves 
 
INVESTIGATIONS – IMAGING TECHNIQUES   CONFIRM  THE  
DIAGNOSIS 
 MRI  -  Establishes  the  anatomy  and  pathology  of   infection. 
 CT  -   Follow  up  of  patients  with  prior  shunt  infection 
To  decide   in  critical care  of   undiagnosed  patients. 
 Post  Obstructive  Hydrocephalus10,11,17  - Dilation  of  lateral  
ventricles  and   obstruction   of  fourth   ventricle. 
 Tuberculous   meningitis         -  prominent          lepto meningeal   
and  basal  cistern   enlargement. 
 USG -  Cranial  ultrasound  for  periventricular    hyper echogenicity   
and   GV IVH     
 germinal  matrix  intra ventricular  haemorrhage (GV IVH)  in  
premature  infants., 
 infants   with  myelomeningocele 
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MICROBIOLOGY   OF  CAUSATIVE  PATHOGEN 
Whenever   possible   adequate   sample  collection   and   immediate  
processing   is  important  for   better   recovery  of  implicated  pathogen  as  a  
complex   polymicrobial   condition   is   involved52. 
Proximal  part  of  shunt  infections  causes  meningitis  or  ventriculitis, 
distal part  of  shunt  infections  causes  fever , anorexia  , abdominal  distension  
and   acute  abdomen53. 
Pathology   in  colonization  causes  Gram  Positive  Organisms   to 
predominate  in   early   onset   infections. Staphylococcus    and   Coagulase  
Negative  Staphylococcus    are  isolated   following   infections   from  upper  
respiratory   illness   or  following   transient   bacteremic   attack  among   
individuals   at  risk54. 
Gram  Negative  Bacteria   has  been   reported  recently  in  tertiary  care  
units.  Post –meningitis   brain  abscess    due  to  citrobacter   in   neonates,  and  
coliforms   with   infection   of   terminal  end  of  shunt  device  and  gastric  
perforation,  has  been  documented  in  a study  by  Kumar  et al5,. 
Stamos ,   Kaufman   and  Yogev   in  their  study   (Ventriculoperitoneal  
shunt  infections  with  Gram  Negative  Bacteria)  suggested  that  GNB  
infections  accounts  for  7-24%  in  all  Ventriculoperitoneal  cases56. Common   
nosocomial   pathogens   involved  are  Enterobacteriaceae  and  Non  
Fermenters,  Pseudomonas  aeruginosa  25%, E.coli  20%, Acinetobacter  are 
15%. Predictors  of  GNB  are  related  to  intraperitoneal  inflammation,  
hematogenous spread and  bowel perforation  of  distal  tip  of  VP  catheter  tip. 
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The   major  concern   of   Gram  Negative  Coliforms   are  increase   in   
antimicrobial   resistance  by   various   mechanisms   by   extended  spectrum   
β- lactamase  or  AmpC  enzymes. In  case  of  Gram  Positive  Organism   ,  
methicillin  -resistant   Staphylococcus  aureus   (MRSA)  and  Vancomycin   
Resistant   Enterococci   (VRE)   are  to  be   considered57. 
 
RESISTANCE   OF  PRIORITY   PATHOGENS 
Injudicious  use  of  antibiotics  have  resulted  in  the  emergence  of  
antibiotic   resistant  strains.  Hence  identification  of  the  species  and  their  
resistant  pattern  is  important  in  the  treatment  of  such  infections58. 
The  increase  in  the  rates  of  antibiotic   resistance  is  a  major  concern  
in  both  non-fermenting  bacilli  and  members  of  the  Enterobacteriaceae  
family.  Antimicrobial  resistance  in  addition  hampers  the  effectiveness  of  
treatment  and    thus  the  patient  remains  infectious  for  a  long  time  thereby  
increasing  the  spread  of  resistant  microorganisms  to  others59.   
In   February  2017  WHO   published  a  list   of  Antibiotic  resistant 
“Priority  Pathogens”  requiring  newer  antimicrobials,  which  is  classified  
into  critical,  high,  and  medium  priority  pathogens.44 
Critical  pathogens  requiring  newer  antibiotics  include  Pseudomonas,  
Acinetobacter,  Enterobacteriaceae  (Proteus,  Klebsiella,  E.coli,  Serratia).  
These  bacteria  are  resistant  to  number  of  antibiotics  including  Penicillin’s,  
III  generation  Cephalosporins&Carbapenems, which is the  best  available  
antibiotic  for  treating  them60. 
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LIST OF “WHO” PRIORITY PATHOGENS REQUIRING NEWER 
ANTIBIOTICS : 
Priority  I :  Critical  
1. Acinetobacter  -carbapenem  resistant. 
2. Pseudomonas  -carbapenem  resistant. 
3. Enterobacteriaceae (Proteus,  Klebsiella,  E.coli,  Serratia)  - carbapenem 
resistant,  ESBL  producing.   
The global  spread   of  Carbapenemase - producing  Gram-negative  
pathogens  is  of  special  concern  in  healthcare  and  community  settings.  
Carbapenemase   confers  resistance  to  most  beta-lactam  antibiotics  including  
penicillin,  cephalosporins  and  carbapenems. Carbapenems   have  emerged  
as  the  agent  of  choice  for  managing   Enterobacteriaceae,  as  they  are  
resistant  to  aminoglycosides,  fluoroquinolones,  Penicillin  and  third  
generation  cephalosporins61.                                
Nosocomial  isolates  of  S. aureus,  Enterococcus  species,  E.coli,  
Klebsiella,  Pseudomonas,  &  Acinetobacter, have  become  multi  drug  
resistant,  extremely  drug  resistant  and  pan-drug  resistant,  producing  beta-
lactamases  including  ESBL, MBL &  Amp - C.  Metallo-β-lactamases (MBL),  
has  the  ability  to  hydrolyse  Penicillins,  Cephalosporins,  and  Carbapenems.              
Phenotypic  methods   includes   combined  disk  diffusion  test,  double  
diffusion  test,  modified  Hodge's test  and  Epsilometer strip  test to identify  
the  Carbapenemase  production  .   Molecular  characterization by PCR is  the  
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only  available  tool  for   MDR,  XDR,  and  PDR  strains,  based  on  
Carbapenemase  encoding  genes.8  PCR,  used  to  identify  the  genes62.   
Early  detection  of  infection    is  critical  in  paediatric  neurosurgery ,  
for  adhering   to  strict  infection  control  practices,  formulating  an  effective  
antibiotic   policy  to  prevent  the  spread  of  these  MBL  producing  strains,  
and  treatment  with  alternative   higher  antimicrobial  agents. 
 Clinical  Infectious  Disease (2017)  suggest  that  incidence  of 
A.baumannii  resistant strains are  increasing  across  the  globe  because  of  its  
tendency  to develop  pan  drug  resistance ( PDR).  PDR  is   defined   as  when  
an   isolate   exhibit  resistance  toall  seven. Anti-pseudomonal agents  which  
includes Anti-pseudomonal penicillins, cephalosporins, carbapenems, 
monobactems, quinolones, aminoglycosides  and   polymyxins63. 
 
I. SHUNT COMPLICATIONS 
1)  Mechanical  Complications 
 Mechanical failure and infection contribute to 90% of 
complications 
 Infection 
 Shunt blockages( proximal ,valve or distal) 
 Fracture or disconnection 
 Migration 
 Over  drainage 
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2)  Biological   Complications 
 Isolation (trapping) of ventricles 
 Malposition 
 Intracranial haemorrhage 
 Viscus perforation 
II.SHUNT BLOCKAGE  
 Shunt obstruction is absolute indication for  shunt revision.  In  the 
majority ,it is due to blockage of ventricular catheter by   cellular debris,  
choroid  plexus  and  brain tissue64. 
III. THE SLIT VENTRICLE SYNDROME 
 Slit ventricle syndrome is a rare symptomatic  condition presenting with 
neuro imaging of small  ventricles  in a patient   with venticulo peritoneal shunt 
and its misinterpretation as a properly working shunt65. 
IV. ABDOMINAL COMPLICATIONS   
Viscus perforation is a result of complication of the   initial insertion  or  
as result of chronic erosion of the catheter tip through the viscus  wall.  Signs 
of peritoneal sepsis or occasional extrusion of the catheter tip at the anus,  
umbilicus or   vagina66. 
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V. INTRA ABDOMINAL FLUID COLLECTION67,68,69 
Abdominal pain   and   distension   are   the   common symptoms  
.Localized collection  of CSF within peritoneal cavity is common.  Ultrasound 
findings   are   confirmatory .  
CLINICAL FEATURES  SUPPORTING   SHUNT  INFECTION 
The clinical  features  of shunt infection are variable,  depending on the 
pathogenesis of infection,  virulence of organism and  type of shunt. 
The most common symptoms are headache ,  nausea,  lethargy and 
changes in mental status (seen in about 65% of infected patients) which occur 
in shunt malfunction secondary to the infection70. 
Fever is reported in  20 – 90%  cases,  and  absence of fever does not 
exclude infection  of  ventriculo  peritoneal  shunt. 
Symptoms and signs are  referable to the proximal or distal portion of 
the shunt. Infection arising in the proximal portion of the shunt causes 
meningitis or ventriculitis  in about 30% of cases with resultant shunt 
obstruction or decreased function71. 
Symptoms referable to the distal portion may be due to peritonitis such 
as fever,  anorexia,  abdominal distension and other signs of acute abdomen.  
Low virulence organisms present   few signs such as abdominal tenderness  and 
guarding .Fluid collections occur  due to encystment  of the shunt catheter tip. 
The  deposited  CSF  is  not  absorbed  causing  loculation  of  pockets  of  fluid 
within  the  abdomen  resulting  in  partial  or  complete  shunt  obstruction  with  
shunt  extrusion  when  Gram  Negative  Bacteria  is   associated. 
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DIAGNOSIS  OF  SHUNT  INFECTION 
The  diagnosis of CSF shunt infections is made by culture of the shunt 
reservoir  fluid  or CSF or  blood  sample  before  administration  of  antibiotics..   
Blood culture is also of limited value in  ventriculoperitoneal  shunt  infection  
but it is positive in up to 90% of vascular shunts72. 
The CSF sample  is subjected to cell count including differential count,  
biochemical  analysis (CSF glucose and protein), gram  stain  and  culture73. 
High white blood cell counts reflect infection,  but infection may be 
present even with normal cell counts.  Normally the CSF has less than 5 
leukocytes  per ml. 
In  case  of  tuberculous  meningitis  ,  gross   appearance  of  CSF  may  
present  with  fibrin  web  and  predominant  mononuclear  cells  more  than 
100-1000  cells /mm3. 
CSF eosinophil count can  be elevated and has been found  to  be 
associated with indolent infection.  Cell counts can  undergo alteration  by 
recent surgery due to inflammatory response or due to spilled blood. 
The  CSF  glucose  levels  may  be  reduced  and  protein  levels  elevated.  
Glucose  levels  may  be  in  the   normal  range  in  most  cases  and  not  very 
useful. 
Gram staining helps  in  denoting  the type  of causative micro organism, 
but  absence  of  bacterial  morphotypes   does  not  exclude the  infection.  CSF 
culture   from the shunt or  reservoir  is the most valuable   in establishing the 
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diagnosis of infection.Cultures are usually positive even in  absence of CSF 
pleocytosis or abnormal biochemical parameters76. 
Cultures may  require several days of incubation  before being discarded 
as negative.  A  positive culture indicates true infection.  In patients  with 
external  ventricular drain,  CSF  pleocytosis and  a  positive  culture  (obtained 
from  the  ventricular  catheter)  indicates  definite  infection. 
Absence of  a positive gram stain of CSF culture  and  a progressive 
decrease in  CSF glucose and increase  in CSF protein with advancing 
pleocytosis indicates a suspected  infection77. 
Patients  with distal occlusion  of VP shunt  and  shunt  extrusion  
presents  as acute  abdomen and they must   undergo  revision surgeries. A CT 
or ultrasound scan of the abdomen  identifies CSF loculations at the terminus.  
Peritoneal symptoms  clear within 12 hours after removal of an infected distal 
catheter. 
FACTORS TO BE CONSIDERED IN THE THERAPY OF AN 
INFECTED CSF SHUNT INCLUDE : 
1. Selection of antimicrobial therapy 
2. Timing of hardware removal 
3. Timing of shunt replacement 
4. Duration of antimicrobial  therapy 
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ANTIMICROBIAL THERAPY&  MANAGEMENT  OF DRUG  
RESISTANCE 78,79  
The antimicrobial agent  of  choice  must  have  greater  distribution  of  
bactericidal   activity  in  central nervous system  which  includes  Ampicillin,   
Ceftriaxone,  and  Meropenem .  Frequently  used  aminoglycoside  
(Gentamycin) and Nucleic  acid  synthesis  inhibitor  (Ciprofloxacin) does  not  
attain  therapeutic   concentration  in  CSF  according   to  Principles  of  
Antimicrobial  action  and   resistance   by  [Bailey  & Scott  14th  
edition].Minimum  Inhibitory  Concentration  of   Carbapenems  is   effective   
method   to  prevent   anti microbial  resistance. 
Direct  instillation  of  antimicrobial   agents  into  the  ventricles  and  
use  of  antibiotic   impregnated  shunts    reduce  the   biofilm   formation  by   
skin  commensals  and  help  in  better  outcome  of  results   to  both  the  patient  
and  tertiary  care   centre12. 
SHUNT  REMOVAL  AND  REPLACEMENT55  
A  new  shunt  is  usually  not  placed  until  CSF  culture  is  negative  
for  bacterial   growth. The  recommend  interval  between  shunt  revision  and   
reinsertion  is   approximately  10 -14  days  with  atleast   48  hours  between   
the  final   negative  CSF  culture  and   reinsertion. 
A  variety  of  methods  are  used  to  support  shunt  deprived  patients  
that   include  shunt  exteriorization,  placement  of  external  ventricular  drain  
or   lumbar  drainage  catheters. 
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Ventriculitis  of  shunt  infection  clear  more  quickly   with  external  
drainage,  the  treatment  success  usually   greater  than  85%  .  The   greatest   
risk  of  the  EVD  is  secondary   infection.. 
 
SHUNT  REINSERTION62 
Shunt   infections  caused  by  CoNS   with  normal  CSF  findings,  and 
negative  cultures   for  48  hours  after  externalization indicates   absence  of  
infection   and  patient  can  be  reshunted  on  the  third  day  after  removal. 
If  CoNS  was  isolated  with  abnormal   CSF   biochemistry   and   
pleocytosis,  7  days  of  antimicrobial  therapy   is   recommended   and  repeat   
CSF  culture  is  advised    before   reshunting. 
For  shunt  infections  caused  by  S.aureus  or  gram  negative  bacilli  ,  
10  days  of  antimicrobial  therapy   is  followed   in  tertiary  care   centres.  
Repeat   CSF  negative   culture   is  recommended  before  reshunting. 
Infections   with   Gram  Negative  Organism   are  difficult  to  treat      
because  of   resistance  offered  and  ability  to  cause  reinfection.  Focus  of  
infection  must  be  identified  which  may  take   its  orgin  in  gastric  fluid,  
peritoneum,  or intestines38.  
Intravenous  antibiotic  treatment  usually  results  in rapid 
bacteriological  clearance  with  resolution  of  the  CSF  pleocytosis  if   standard  
protocols  are  followed. 
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PREVENTION 
Meta – analyses   have   concluded   that  prophylactic    antibiotics   can  
reduce  of  infection   by  about  50%.Antibiotic  impregnated   catheters   for  
EVD  and  CSF  shunts  have  been   shown  to  reduce  colonization  and  
infection   of  the  catheter  with  gram – positive  organism37. 
Expanded  poly-tetra-fluro-ethylene  VP  shunt  is  alternative  to  silicone  
VP  shunts.  Newer  advancements   are  Poly  Hydroxyl  Ethyl  Metha  Acrylate  
(p HEMA)  and  Poly-Vinyl  Pyrrolidone  for  surface  functionalization.  Radio 
opaque  indicators,  typically  utilizing  Barium  sulfate  or  tantalum  are  
incorporated  for better clinical outcome. 
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MATERIALS  AND  METHODS 
Places  of   study:  
The  study  of  “ Ventriculoperitoneal  shunt  infections  in  paediatric  
patients”  was  conducted  in  the  Department  of  Microbiology,  Coimbatore  
Medical  College  Hospital  among 60 paediatric cases. CSF, shunt tip and blood 
samples  were collected  in  Neurosurgical Operation Theatres   from  children  
with  signs  and  symptoms  of  infection  following  the  first  
ventriculoperitoneal  shunt  surgery  in  post  operative  period . Extraventricular   
drain  was   established  and  samples were collected for microbiological, 
biochemical and cytological analysis  to  document  the  etiological  agents  of  
Ventriculoperitoneal  shunt  infections. 
Study  Period: 
The  study  was  conducted  for  a  period  of  one  year  from  March  
2017  to  June   2018.  
Type   of   Study:  Prospective  study 
Approval  from  the  ethical  committee  was  obtained  prior  to  the  
conduct  of  the  study.  
Ethical  clearance:  
As this study  involved  the  collection  of  clinical  samples  from  
paediatric patients  in Operation  Theatres,  ethical  clearance  was  obtained  
before  the  commencement  of  the  study.  
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Informed  consent:  
Informed consent was obtained  from  all  parents whose children were 
involved in  the  study.  A  filled  in  proforma  was  obtained  from  parents  of  
paediatric  patients   with  the  details  including  Name,  Age,  Sex,  Ward,  
Clinical  Diagnosis,  Risk  factors,  Antenatal,  Natal,  Post-natal, history & age  
of  insertion  of  first  and  subsequent  ventriculoperitoneal  shunts  with  follow 
up.  
Sample 
In  the  present   study   CSF sample , blood  sample , shunt  tip  samples  
from  60  paediatric patients  who  have  undergone  ventriculoperitoneal   shunt  
surgery   due  to prematurity ,  anatomical  defect,  infective  pathology,  post  
traumatic hydrocephalus  and  hydrocephalus  following  posterior  fossa  
tumours   were   obtained.  
Inclusion  Criteria 
Paediatric   patients    who  have  undergone   ventriculoperitoneal  shunt  
surgeries  with  following  criteria  were  included  in  the  study:    
1) Signs  and  symptoms  suggestive  of  acute  bacterial  meningitis 
2) Shunt  obstruction 
3) Shunt  malfunction 
ExclusionCriteria 
1. Patients  who  have  skin  infections. 
2. Patients   with  focal  sepsis   and  terminating  illness. 
3. Immunocompromised  patients   with   hydrocephalus 
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4. Patients  who  have  no  signs  and  symptoms   of  infection  after   
surgery. 
5. Adults  above   13  yrs 
COLLECTION  AND   TRANSPORT  OF  SAMPLES : 
The  samples   were   collected  from  Neuro  Surgery  Operation  Theatre   
of  both  Elective   and  Emergency   posted  cases. Samples  were   transported  
to  Microbiology  department   and  processed   without  delay. 
SAMPLE  COLLECTION : 
 Autoclaved   screw  caped   container   for   CSF  sample. –   SAMPLE  1 
 Autoclaved  screw  caped  container  for  CSF  shunt  tip _ SAMPLE  2 
 2ml  blood  sample   in  10 ml  of  Thioglycollate  broth  _   SAMPLE  3                  
PROCESSING  OF  SAMPLES  INCLUDES 
 MICROBIOLOGICAL  PROCESSING OF  SAMPLE 1,2,3. 
 BIOCHEMICAL  ANALYSIS  OF  CSF 
 CELL  CYTOLOGY  STUDY    OF  CSF 
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MICROBIOLOGICAL  PROCESSING 
 PROTOCOL  FOLLOWED: 
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MULTIVARIATE  ANALYSIS  OF  SAMPLES  IN  THIS  STUDY 
Microbiological                 Isolation of organism                     Gold Standard Method 
                          Processing 
 
 
CSF  Biochemical Analysis   CSF Glucose Normal (40-70 mg/dl) 
  ( Decreased in ABM) 
 
 
       CSF Albumin upper limit (150 mg/dl)   
       (Increased in ABM) 
 
 
       CSF Protein Normal (15-50 mg/dl)  
  (Increased in ABM) 
 
 
         CSF LDH Normal in neonates (upto 70 IU/L)   
  ( If Increased indicates sign of brain injury) 
 
        Cell Cytology 
       Monocytes (tuberculous meningits) 
     (Normal < 5 Cells /cumm) 
    
       Poly morphs( Bacterial meningitis) 
 
       Nil Polymorphs(Viral Meningitis) 
 
 
CSF: 
MACROSCOPY  EXAMINATION  : 
1) Naked eye examination of CSF  to  observe  if  clear,  turbid,  
purulent,  blood stained,  cobweb  appearance  is  present  or  absent. 
2) In  case  of  centrifuged  CSF  samples  the   deposit  provides  
better  information  of  pus  cells  and  bacteria for  screening  with  
microscope. 
MICROSCOPIC  EXAMINATION  : 
CSF  samples  may  have  scanty  cells  and  bacteria ,  hence   a  thick  
smear  or  a  heap-up   technique  with  oval  marking  on  under  surface  of  
slide  is  done  and  heat  fixed  .Gram   stain  is  performed  by  Hucker   method  
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and  observation  is  under  100X . In  case  of  purulent   CSF,   thin   smear   is  
done   for  better  interpretation  and  heat  fixed  followed  by  Gram  staining. 
The  smear  is  heat  fixed  with   methanol  so  that  it  provides  relevant  
information   for   documentation  in  future. 
On  day  2  if   there  is  evidence  of  growth  it  must  be  followed  by  
(Hanging   drop) motility  test.  Few  colonies  are  taken   from  culture enriched  
in  peptone  water  for  20  minutes  and  then    Hanging  drop  method  is  
performed   to  clearly  delineate  motile   and  non  motile  bacteria. The  edge  
of  drop  is  seen  under  10X  and  the  edge  is  carefully  turned  to    high  
power  40X  to  observe  for  motility. 
 
CONVENTIONAL  CULTURE  METHODS  FOR  AEROBIC   
CULTURE: 
1) CSF  and  shunt  sample  for  recovery  of  fastidious  organisms, were  
inoculated  into  Chocolate  agar,  Mac Conkey  agar  and  Blood agar  
plates  and  incubated  for  37C  in  5-10%  carbon  dioxide  in  a  candle  
jar   for  18  to  72  hrs.   
2) For  recovery  of  Non fastidious   organisms , CSF  and  shunt  tip   
samples  were   inoculated  into  Nutrient  agar  plate   and  MacConkey  
agar  plate. 
3) Colony  morphology was  studied   with   Gram’s  stain  and  motility  
of  the  organism  was  confirmed  on  second  day. Isolated  growth  of  
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colonies  were  subjected  to  biochemical  reactions  and  antibiotic  
sensitivity  test. 
4) Shunt  tips    were   processed  by   rolling  the   tip  over  the  surface  
of  media   and  transferred   the  shunt  tip  to   Brain  Heart  Infusion  
broth  by  using   sterile   forceps. 
5) 1  to  2  ml  of   blood  is  collected   in   10  ml  of   Thioglycollate   
broth  and  subcultured  after  48  hrs  in  BAP,  CAP  and  Mac  Conkey  
agar  plate. 
 
PROCESSING  AND  FURTHER  IDENTIFICATION   OF  
ANAEROBIC  BACTERIA : 
PRINCIPLE   :  
Anaerobiosis  is  created  by  displacing  oxygen  from  the  jar  by  
chemical  methods. In  this  method  a  sachet  containing  sodium  bicarbonate   
and   sodium  borohydride  which  react  chemically  in  presence  of  water  ,to 
produce   hydrogen  and  carbondioxide  is  used. 
Anaerobic   culture   of  Cerebrospinal  fluid  is  done  with  CSF  sample   
enriched  in  thioglycollate  broth  for  48 hrs,  later  subcultured  on   CDC  
Anaerobic  Blood    agar  plate  by  streak  culture  method and placed in Gaspak 
anaerobic  jar.    Pseudomonas  aeruginosa  ATCCC  27853 which  is  a  obligate 
aerobe  is  used  as  a  biological  indicator  and  methylene  blue  as  a chemical  
indicator  is  used  to  check  the   effectiveness  of   anaerobiosis. 
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The  plates  are  observed  for  the  colony  characteristics, hemolysis  
and  pigmentation  at   regular  intervals. If  no  growth  is  observed  at  the  end  
of  24 hrs  continued  incubation  for  48 hrs and  extend  upto  seven  days. 
Isolation  of   growth  is  confirmed  with  Gram  stained  smear  from  colonies  
to  identify   obligate  anaerobes. 
No  anaerobic  were  isolated  from  any  of  the  samples. 
 
BIOCHEMICAL  REACTIONS:  
As  per  NCCLS  guidelines  the  following  biochemical  reactions  are  
done. 
 
BIOCHEMICAL  REACTIONS 
Reactions  in  favour  
of  Gram Positive 
Organisms 
Reactions  in  favour  of 
both  GPC  &  GNB 
Reaction in favour of  
GramNegative 
Organisms 
 
 Coagulase test 
 
 Catalase  test 
 Urease   test 
 VogesProskauer test 
 Hugh Leifson's(OF) 
test 
 Indole  test 
 Citrate 
 Triple  sugar  ion 
 Methyl  red   
 Decarboxylase  
 Nitrate  test  
 Fermentation  test 
 MMM test 
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COAGULASE  TEST  - 
Purpose  of  this  test-  
1)  To  test  the  unique  property  of  clotting  of  plasma  by  Staphylococcus  
aureus  which   secretes  coagulase  enzyme  . 
2) Definitive  test  for  Staphylococcus  aureus  and   it   contributes  for  
virulence. 
It  differentiates  S.aureus  from  Coagulase  Negative  Staphylococci.  
Slide  coagulase  test  and  Tube  Coagulase  test  are  two  methods  involed  in  
this  test. 
a) SLIDE  COAGULASE  TEST 
This  test  detects  the  presence  of  bound  coagulase .   Suspected  growth  
of   white   opaque  colonies  are  to  be  emulsified  in sterile  saline  to  form  
a  milky  suspension  on  a  clean  glass  slide  .  A  drop  of  citrated  plasma  is  
added  to  milky  suspension  and  observed  for  visible  clumps  within  10  
secs. Control  is  made  with  Staphylococcus  aureus  ATCC 25923  to  avoid  
false  positive  results. 
b) TUBE  COAGULASE  TEST  
This  test  detects  the  presence  of  free  coagulase .  To  0.5ml  of  
overnight  broth  pure  culture  of  Staphylococcus  add  0.5ml  of   fresh  plasma  
incubated  in  a  waterbath  at  370C . Every  30  minutes  ,  the  test tube  is  
tilted  and  observe  for  clot  formation  upto  4hrs. Positive   controls  are  kept.  
Readings  are  observed  at  end  of second  and  fourth  hour   respectively. 
Formation  of  a  firm  clot  is  positive  for  enzyme  coagulase 
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CATALASE   TEST: ( Tube  method). 
Purpose  of  this  test- 1)To  prevent  accumulation  of   Hydrogen   peroxide   
and  catalyse  the  reaction  so  that  it  converts  this  lethal  reagent  into  water  
and  oxygen. 
2) Differentiate  members  of  Micrococcaceae  from  members  of  
Streptococcaceae. 
Procedure  
1)  Slide  method   
2) Tube   method. 
Few  individual   colonies  to  be  tested  were  picked  up  by  a  sterile  
glass  rod  and  introduced  into  sterile  glass  test  tube  containing  3%  
hydrogen  peroxide.  production of immediate  brisk effervescence within 30 
seconds indicates  catalase  production 
OXIDASE  TEST (Wet  filter  paper  method):  
Purpose  of  this  test  -  All  enterobacteriaceae  are  oxidase  negative.  
Procedure  
WET FILTER  PAPER  METHOD  - 
Freshly  prepared  reagent  is  used  in  this  test  .Oxidase  reagent  (tetra 
methyl  p-phenylene  diamine  dihydrochloride) was  placed  in  a  petri dish  
and  the  colony  to  be  tested  was  smeared  on  the  filter  paper.  If  it  turns  
into  deep purple  in   10 seconds    the  organism  is  oxidase  positive. 
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INDOLE:  
Purpose  of  this  test  - 1)  Ability  of  organism  to  split  tryptophan. 
This  test  demonstrates  the  production  of  indole  by  spliting  
tryptophan  into  indole  and  pyruvic  acid. 2 ml  of  24-48  hour  broth  culture  
was  taken  in  a  test  tube  and  to  this  0.5ml  Kovac’s  reagent  was  added  
gently  along  the  sides.  Formation  of  a  red  colour  ring  at  the  junction  
was  taken  as  a  positive  test. 
 
CITRATE  UTILIZATION  TEST:    
Purpose  of  this  test  -  Citrate  is  used  as  sole  source  of  carbon.   
The  organisms  were  streaked  on  the  surface  of  a  slant  of  Simmon’s  
citrate  medium  and  incubated  at  37ºC  for  18-24  hours.  Development  of  
deep  blue  colour  of  the  medium   indicates    presence  of  growth  and  its  
taken  as  citrate positive.    
UREASE  TEST:  
Purpose  of  this  test  -  Ability  of   organism  to  split  urease  enzyme 
The  organism  was  streaked  on  the  slope of  Christensen’s  urease  
medium  and  incubated  at  37ºC  for  18-24  hours.  Urease  positive  cultures  
produced  a  pink  colour.  
METHYL  RED  TEST:  
Purpose  of  this  test  -  Quantitative  test  for  detection  of   acid  production. 
A  pure  culture  of  the  test  organism  was  inoculated  into  5  ml  of  
glucose  phosphate  broth  and  incubated  for  48-72  hours  at  35°C.  To  this  
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5  drops  of  methyl  red  reagent  was  added.  The  development  of  bright  red  
colour  indicates a  positive  test.  
VOGES-PROSKAUER  TEST:   
Purpose  of  this  test -  To  identify  those  bacteria  that  produce  acetoin  as  
chief  end  product  of  glucose  fermentation 
Glucose  phosphate  broth  (5  ml)  was  inoculated  with    a  pure  culture  
of  the  test  organism  and  incubated  at  35°C  for  24  hours  and  to  this  0.6  
ml  of  5%    alpha  naphthol  followed  by  0.2ml  of  40%  KOH  was  added  
and  shaken  gently.  Acetoin  formation  was  indicated  by  the  appearance  of  
eosin  pink  colour   in 10  minute 
TRIPLE  SUGAR  IRON  AGAR  MEDIUM  (TSI): 
The  composite  solid  agar  medium  contains  3  sugars  glucose,  lactose  
and  sucrose.  The  medium  was  distributed  in  tubes  with  a  butt  and  slant 
. Using   a  straight  wire,  the  organism  from  primary  isolation  plate  was  
stabbed  into   the  butt  and  streaked  on  the  slant.  TSI  was  incubated  for  
18-24  hours  at  37ºC,  and    observed  for  the  presence  of  growth  and  
fermentation.  Phenol  red  is  used  as  indicator  of  acid  production  and  Ferric  
salts  as  an  indicator  of  hydrogen  sulphide  production. 
Interpretation:  
Acid (A)  /  Acid  (A):  Glucose,  lactose  &   sucrose  fermented  which  is  
characteristic  of  lactose  fermenting  bacteria  such  as  E.coli  &  Klebsiella,  
with  or  without  production  of  gas . 
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Alkaline(K)  /  No  change (NC)  :  No  fermentation  of  carbohydrates,  
characteristic  of  non  fermenting  bacteria  such  as  Pseudomonas  &  
Acinetobacter. 
Alkaline(K)  /  Acid(A) with H2S & Gas : Non  Lactose  fermenters  showed  
alkaline  slant,  and  fermentation  of  butt,  with  production  of  abundant  H2S  
&  gas  production .  This   is  typical   of   Proteus  and  Salmonella  paratyphi 
B  infection. 
DECARBOXYLASE &  DIHYDROLASE TEST:  
Purpose  of  this  test – It  measures  the  enzymatic  ability  of  an  organism  
to  decarboxylate  an  amino  acid  to  form  amines.  
Few   isolated  colonies  from  the  nutrient  agar  plate  were  inoculated  
in  4  tubes  of  Moller`s  decarboxylase  medium    containing     lysine,  ornithine 
and  arginine  hydrochloride  and  control.  Sterile  mineral  oil  was  overlaid 
on  the  surface  of  the  tubes  and  incubated  at  35°C  for  18-24  hours.  Purple  
colour  change  indicates  that  the  test  was  positive. 
 
OXIDATION  FERMENTATION  TEST  (HUGH  AND  LEIFSON’s) 
Purpose  of  this  test  -This  test  is  used  to  differentiate  between  oxidation  
and  fermentative  reaction. 
Two  tubes  containing  OF  medium  were  inoculated  heavily  with  the  
isolated  colonies  using  a  sterile  loop.  One  tube  was  covered  with  a  1 cm  
layer  of  sterile  mineral  oil  and  other  tube  remained  open.  Both  tubes  
were  incubated  at  35°c  in  ambient  air  and  examined  daily  for  2-3  days.   
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CARBOHYDRATE  FERMENTATION  TESTS:  
Purpose  of  this  test-  It  detects  ability  of  organism  to  ferment  specific  
sugar  incorporated  into  the  medium  with  production  of  acid  with  or  
without  gas. 
Sugars  like  1%  glucose,  1%  sucrose,  1%  lactose,  1%  maltose  and  
1%  mannose  were  tested  individually  for  oxidative  utilization.  The   
medium  turns  yellow  with  acid  production  by  bacteria.   
MANNITOL  MOTILITY  TEST:  
Purpose  of  this  test -  To  demonstrate  the  motility  of  organism. 
A  pure  colony  was  picked  using  a  straight  wire    and  stabbed  in  
the  middle  of  about  half  the  depth  of  the  mannitol  motility  medium  and  
incubated for  18-  24  hours  at  35°C.  
Interpretation:  
Motile:  Diffuse  zone  of  growth  flaring  out  from  the  streak  line  .  
Non  motile:  organisms  were  confined  to   the  line  of  inoculation 
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Processsing of  Gram –positive  cocci  in  clusters 
 
                                                     catalase 
 
 
 
             Positive                                                              Negative 
 
 
i) Staphylococcus species                          Streptococcus species                                 
ii) Micrococcus  species                              Stomatococcus  species 
 
 
 
Staphylococcus species                                          Micrococcus  species                               
1. Modified oxidase – (Negative) 
2. Furazolidone 100µg – (sensitive) 
3. Bacitracin  0.04 U – (Resistant) 
4. Modified Hugh- Leifson 
         O/F  test – fermentative 
 
 
 
 
 
 
 
 
 
 
1. Modified oxidsase – (Positive) 
2. Furazolidone 100µg – (Resistant) 
3. Bacitracin  0.04 U – (sensitive) 
4. Modified Hugh- Leifson 
         O/F  test-oxidativ
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A  battery  of  Biochemical  reactions  to  identify  various  species  of  CoNS  were  
put  up  and  identification  done  as  follows. 
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Pigmentation present absent variable variable 
Bound  coagulase + - - - 
Tube  coagulase + _ _ slow 
Ornithine 
decarboxylase 
- - - + 
Mannitol  to  acid + _ + _ 
Urease  test hydrolysed - hydrolysed - 
Trehalose   to  acid + _ + + 
 
DETECTION  OF  ANTIMICROBIAL  SUSCEPTIBILITY   PATTERN: 
Antimicrobial  susceptibility  was  done  in  Muller  - Hinton  Agar plate  by  
Kirby -Bauer  Disc  diffusion  method  with  test   inoculum  0.5  McFarland  lawn  
culture.  and  overnight  incubation  with  the  following  ATCC  control  strains. 
ATCC  CONTROL  STRAINS: 
Staph  aureus  -ATCC  25923 
E.coli            - ATCC  25922 
Pseudomonas  – ATCC  27853           
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Antibiotic  panel   for Gram  Positive  Organism 
The  antibiotics  used  for  Gram  Positive  Cocci  were  Penicillin  (10 U), 
Cefoxitin (30 mcg),  Trimethoprim-sulfamethoxazole (1.25/23.75 mcg),  Linezolid 
(30 mg),  Amikacin (30 mcg) ,  MIC   for  Vancomycin  and  Colistin 
Antibiotic  panel   for  Lactose  fermenter : 
The  antibiotics  used  for   Gram-Negative  Bacilli  were Ampicillin (10 
mcg), P ipracillin/tazobactam  (100/10 mcg),  Ceftazidime  (30 mcg),  Ceftriaxone  
(30 mcg), Cefepime  (30 mcg),  Ceftazidime / clavulanic  acid  (75/30 mcg),  
Amikacin  (30 mcg), Gentamicin  (10 mcg), Netilmicin               (30 mcg),  Imipenem 
(10 mcg),  Meropenem  (10 mcg), Aztreonam  (30 mcg),  Polymyxin B  (300 mcg),  
Colistin (10 mcg), Trimethoprim  sulfamethaxazole  (1.25/23.75 mcg). 
Antibiotic  panel  for  Non-Lactose  Fermenter : 
Antibiotics used for Pseudomonas aeruginosa were Piperacillin (100 mcg), 
Piperacillin/tazobactam (100/10 mcg), Ceftazidime (30 mcg), Cefepime (30 mcg), 
Amikacin (10 mcg), Gentamicin (10 mcg), Imipenem (10 mcg), Meropenem (10 
mcg), Netilmicin (30 mcg), Aztreonam (30 mcg), Polymyxin B (300 mcg), Colistin 
(10 mcg).  
ANTIBIOTIC  SUSCEPTIBILITY  TESTING: 
This  test  was  done  by  modified  Kirby-Bauer  disc  diffusion  technique  
using  Mueller  Hinton  agar.  A  single  colony  of  the  test  organism  was  taken  
from  the  plate  with  a  wire  loop,  and  was  inoculated  into  peptone  water  and  
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incubated  for  18- 24  hrs  at  37oC.  The  result  was  matched  with  0.5  McFarland  
turbidity  standard. 
Preparation  of  0.5  McFarland  standards  
1. Prepare  1%  w/v  solution  of  Sulphuric  acid  by  adding  1ml  of  
concentrated  sulphuric  acid  to  99  ml  of  water.  Mix  well.  
2. Prepare  1%  w/v  solution  of  barium  chloride  by  dissolving  0.5g  
of  dehydrated  barium  chloride  in  50ml  of  distilled  water.  
This  can  be  stored  at  room  temperature  for  up  to  six  months.  The  
0.5  McFarland  standard  provides  an  optical  density  equivalent  to  the  density  
of  1.5    108  colony  forming  units/ml.   
AST  by  Kirby-  Bauer  method:  
1) Mueller-Hinton  agar  was  prepared  according  to  the  manufacturer’s  
instructions  and    poured  into  9cm  diameter  petri  dishes  to  a  depth  of  
4mm.   
2) Antibiotic  Discs  were  stored  in  a  tightly  sealed  container  with  
desiccant  at 2oc  to 8oc. Before  opening  the  container,  discs  were  allowed  
to  equilibrate  to  room  temperature  for  one  to  two  hours  to  minimize  
condensation  and  to  reduce  the  possibility  of  moisture  affecting  the  
concentration  of  antimicrobial  agents 
3) All  the  isolates  were  tested  for  Antibiotic  susceptibility  pattern,  based  
on  CLSI  guidelines.  
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Test  to  report    [Pencillinase –Labile Pencillins]  -  (CLSI-2018) 
Penicillins should  be  used  to  test  the  susceptibility  of all staphylococcus. 
Penicillin  discs 10units are placed on the MHA agar plate, and observed after 
overnight  incubation.  Zone size  of  more  than  29mm is  considered  to  be  
sensitive  and  zone  size  less  than  28  is  Resistant.  
Test to report Pencillinase –Stable  Pencillins -  (CLSI-2018) 
Cefoxitin  is  tested  as  a  surrogate  marker   for  oxacillin.  The   test  is  
done    with  30mcg  cefoxitin  disk ,  the    zone  size  of   more  than  22mm  is  
considerd  to  be  sensitive  and  when  its  less  than  21mm its  considered   to  be 
resistant  for  Staph aureus. 
In  case  of  CONS,  the  sensitive  zone  must  be more  than   25mm   and  
less  than  24mm is  considered  as  resistant. 
E  strips  for  detecting  MIC  for  Vancomycin : 
MIC  tests  by  E  strips were  done  to  determine  the  susceptibility  of  all  
isolates  of   Staphylococcus  to  Vancomycin,  for  Gram  Positive  Organisms. 
For S.aureus  ≤ 2mg/mL  was  considered  to  be   sensitive  and   ≥ 16mg/mL  was  
considered  to  be  resistant. 
For  CoNS  ≤ 4mg/mL  was considered  to  be  sensitive  and  ≥32mg/mL  to  be  
considered  to  be  resistant. 
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GRAM  NEGATIVE  ORGANISMS: 
EXTENDED   SPECTRUM   β LACTAMASE  (ESBL )  DETECTION : 
1) SCREENING  METHODS- STANDARD  DISC  DIFFUSION  
PROCEDURE 
Isolates  of  gram  negative  bacilli  showing  the  following  resistance  
pattern  were  taken  to be  ESBL  producing  strains. 
Antibiotic  zone  diameter  for  possible  ESBL  producing  strains: 
 Cefpodoxime  (10µg ) )  ≤  17mm 
 Ceftazidime( 30µ g)  ≤  22mm 
 Cefotaxime( 30µ g)  ≤  27mm 
 Ceftriaxone( 30µ g)  ≤  25mm 
 Aztreonam( 30µ g)  ≤  27mm 
 
2) CONFIRMATORY   TEST  -STANDARD  DISC  DIFFUSION  
PROCEDURE 
With  a  sterile  bacteriological  loop,  3-5  identical  colonies  were  picked   
from  culture  grown  overnight  and  inoculated  into  5 ml  of nutrient  broth.  The  
broth  was  incubated  at 35º C  for  2-4  hrs  and  turbidity  matched  with  0.5 
McFarland   standard . Lawn  culture  of  the   test  organism  was  made  on  MHA  
plate . Antibiotic  discs  1) Ceftazidime  (CAZ 30µg  )  and  Ceftazidime  with  
clavunate  ( CAC 30µg/ 10µg)   2)  Cefotaxime  (CTX  30µg)  and  Cefotaxime 
with  clavunate  (CEC 30µg/ 10µg)  were  placed  on  the plate  and  incubated   at  
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37ºC  overnight.  An   increase  in  zone  diameter  of  5mm  or  more  for  
Ceftazidime  with  Clavunate   and  Cefotaxime  with  Clavunate than  their  
corresponding  cephalosporin  is  confirmatory. 
4 )  ESBL  DETECTION   STRIP  METHOD 
The  ESBL  detection  strip  is  coated  with  Ceftazidime , Cefotaxime   and   
Cefepime  on  the  upper  half  and  lower  half  has the  above  drugs  with  
clavulanic  acid  and   tazobactam  mixture in  a concentration  gradient.   3 to   5 
colonies of overnight  culture  of  the  organism  is  transferred  to  a  BHI  broth  
and  turbidity   matched  to  0.5 McFarland  standard.  The  suspension  is  streaked  
on  a  MHA  plate  with  a  sterile  swab  and  a  Ezy  MIC  strip  is  placed  on it  
with an  applicator  and   incubated.  The  value  of  MIC  is  read  where  the  ellipse   
intersects   the  scale  on the  strip . 
DETERMINATION  OF  MIC  FOR  MEROPENEM  AND  COLISTIN   BY  
EPSILOMETER  OR  E –STRIP  METHOD. 
E  strip   is  a  Quantitative  method  of  detecting  MIC  by   applying   
principles  of  both  dilution  and  diffusion   of  antibiotic  into  the  medium.  E-
strips  of  Colistin  and  Meropenem   which  contain   predefined   gradient  of  
antibiotic  concentration  immobilised  in  its  length.  Following    incubation  of  
the  test  organism,  an  elliptical  zone  of  inhibition  is  produced  surrounding  
the  strip.  The   antibiotic  concentration  at  which  the  ellipse  edge  intersects  
the  strip  gives  the  Minimal  Inhibitory  Concentration  of  the drug. 
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PHENOTYPIC  METHODS    TO  DETECT  METALLO  -BETA- 
LACTAMASES: 
1. IMIPENEM  AND  IMIPENEM  EDTA  COMBINED  DISC  
TEST(CDT):  
2. MEROPENEM-  EDTA  DOUBLE  DISC  SYNERGY  TEST(DDST):  
3. MBL  E  TEST:  
1)  IMIPENEM  AND .IMIPENEM-EDTA  COMBINED  DISC  TEST  
(CDT):  
The  0.5M  EDTA  solution  was  prepared  by  dissolving  18.61  g  of  
EDTA  in  100ml  of  distilled  water  and  pH  was  adjusted  to  8  using  sodium  
hydroxide.  The  prepared  solution  was  sterilized  by  autoclaving.  The  test  
organism  was  inoculated  on  to  Mueller Hinton  agar  according  to  the  CLSI  
guidelines.  Then  two  Imipenem   discs   (Hi  Media) each  of  10µg   concentration  
were  placed  15-20mm  apart  on  the  plate  and  appropriately  10  µL  of  EDTA  
solution  were  added  to  one  imipenem  disc  with  the  help  of  a  micropipette  
to  obtain  the  desired  concentration  of  750µg.  The  plates  were  incubated  for  
16  to  18  hours  at  37◦C  and  the  inhibition  zones  of  the  combined  disc  and  
Imipenem  disc  alone  were  compared.    
In  this   test,  if  there  is  ≥  7mm  increase  in  the  zone  of  inhibition  around  
Imipenem  EDTA  combined  disc  than  Imipenem  disc  alone,  then  the  test  is  
positive.  It  indicates  that  the  test  organism  produces  Metallo-beta-lactamase  
enzymes.  
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II.MEROPENEM-  EDTA  DOUBLE  DISC  SYNERGY  TEST(DD 
The  organisms  to  be   tested  were  inoculated  on  to  the  Mueller  Hinton  
agar  plate  as  per  the  CLSI  guidelines  .  A  10µg  Meropenem  disc  was  placed  
on  the  MHA  plate  at  a  distance  of  20  mm  centre  to  centre  from  the  EDTA  
disc  (with  10µL  of  0.5M  EDTA  to  get  the  required  750µg  concentration).  
The  MHA  plate  is  then  incubated  at  37◦C  for  a  duration  of  about  16-18  
hours.  If  there  was  enhancement  in  the  inhibition  zone  of  >  5  mm  in  the   
EDTA  disc  than  the  Meropenem  disc  the  test  is  positive. The  test  organism  
is identified  as  a  Metallo-beta-lactamase  producer.  
3 )  MBL  E  TEST 
MBL  E  test  strip  is  a  unique  strip  for  the  phenotypic  detection  of  
MBL  &  is  coated  with  mixture  of  Meropenem  +  EDTA  and  Meropenem  in  
a  concentration  gradient  manner.  The  strip  is  made  of  porous  material  and  
the  antibiotics  are  distributed  evenly  on  either  side  of  the  strip.  It  was  used  
to  determine  the  minimum  inhibitory  concentration  of  the  drug  for  the  test  
strain.  E  test  MBL  strip  has  a  double  sided  antibiotic  concentration  in  a  
range  of  Meropenem  (MP)  0.125  to  8  µg/ml  and  Meropenem  +  EDTA  
(MPI)  0.032  to  2  µg/ml  with  a  fixed  concentration  of  EDTA.  
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Procedure:  
The  inoculum  was  prepared  with  4-5  colonies  from  24  hr  young  broth  
culture  and  inoculated  as  a  lawn  culture  on  Muller  Hinton  agar  after  adjusting  
the  turbidity  to  0.5  Mc  Far land  standards.  The  MBL  E  test  strip  container  
was  taken  from  the  freezer  and  kept  at  room  temperature  for  15  minutes  
before  opening.  The  strip  was  then  taken  with  a  sterile  forceps  or  E  test  
applicator  and  applied  to  the  dried  agar  surface  with  the  MIC  scale  facing  
upwards.  The  plate  was  incubated  aerobically  for  16-18  hrs  at  370C.    
Interpretation: 
The  MIC  of  the  isolate  was  read  where  the  zone  of  inhibition  intersects  
the  strip.  The  MIC  for  MP/MPI  ≥  8  or  formation  of  an  ellipse  was  considered  
positive  for  MBL  production.  
  
Fig 1: Ventriculoperitoneal Shunt placement in a one year baby 
 
 
     
Fig 3: Infected  ventricular and 
peritoneal catheter tips in BHI broth 
 
 
 
 
 
 
 
 
 
 
  
 
Fig 2: Ventriculoperitoneal shunt tube  
 
Fig 4: Direct Gram stain of CSF showing pus cells and GPC 
 
 
Fig 5: Direct Gram stain of CSF showing  pus cells and Gram Negative Bacilli 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
Fig 7: Tube coagulase test of 
Staphylococcus aureus 
 
 
Fig 8: A. Mannitol non fermenting colonies of CoNS  
            B. Mannitol fermenting colonies  of  staph aureus 
A B 
Positive  Negative   
Fig 6: Beta  hemolytic  colonies  of   
Staphylococcus  aureus in   5%  sheep  blood  agar 
 
Fig 9: Escherichia coli on McConkey Agar 
 
 
 
 
 
 
  
Fig 10: Pigment producing Pseudomonas 
on Nutrient agar plate 
 
Fig 11: Pale lactose fermenting colonies of 
Acinetobacter 
 
Figure 12:  Antibiotic  Sensitivity of  Staphylococcus  aureus   
(CX – Resistant)  by disc  diffusion  method 
 
Fig 13: AST by Kirby – Bauer Method (Mueller Hinton Agar) 
Resistant to Meropenem 
 
 
Fig 14: AST by Kirby – Bauer Method (Mueller Hinton Agar)  for CoNS 
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Fig 15: MIC of Vancomycin for S.aureus  
 
 
 
Fig 16: Vancomycin E-Strips shows sensitive pattern for both; 
 A. Staph aureus  (≤ 2μg/ml)      B. CoNS (≤ 4 μg/ml) 
 
  
 Fig 17: ESBL detection by Combined  Disc Method. 
  
 
Fig 18: ESBL Detection by E-Strip Method 
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CAC 
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CEC 
CTX No zone 
CEC ellipsoid  zone 
 Fig 19: Acinetobacter sensitive to NET-15mm, LE-17mm & TGC-21mm 
 
 
 
 
  
Fig 21: E-strip method Meropenem with 
and without EDTA 
Fig 20: Detection of MBL resistance 
pattern in Acinetobacter .  
1. Imipenam and Imipenam + EDTA  
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RESULTS  
 The  study  “Ventriculoperitoneal  shunt  infection  in  paediatric  patients”  
included a total of 60 paediatric patients who have undergone  Ventriculoperitoneal  
shunt  surgery  at  Coimbatore  Medical  College  for  a  period  of  15  months  
from  March  2017  to  June  2018.  CSF  sample  ,  shunt  tip  sample  and  peripheral  
blood  from  these  patients  were  cultured  and  the  organisms  isolated   were  
identified  and  analysed  for  antibiotic  resistance  pattern.  
TABLE  1: DISTRIBUTION OF   CASES   WITH  VP  SHUNT  
INFECTION. (N= 60)  
  
No of Cases N=60  
Percentage  
CULTURE POSITIVE  10  16.66%  
CULTURE NEGATIVE  50  83.34%  
  
Out  of  60 patients  who  underwent  Ventriculoperitoneal  shunt  surgery                 
10  cases(17%)  were  culture positive  and   50 cases(83%) were culture negative.  
Gender distribution  was  not of much significance except for a slight male 
preponderance.   
    
TABLE  2  :  AGE  DISTRIBUTION (n=60)  
Age Category  No  of  patients  Percentage  
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Less than 1 year  29  48.3  
1 year to 5 years  22  36.7  
More than 5 years  9  15.0  
Total  60  100.0  
 
 Patients  in  the  age  group  less  than  one  year  had  increased  risk  of  infection   
(48%)   when  compared  with  age  groups  (1  to  5  years)  and  more  than  5  
years.  
TABLE 3 : CLINICAL   PRESENTATION   OF  PATIENTS   WITH   
VENTRICULOPERITONEAL  SHUNT  INFECTION  
SYMPTOMS  
NO  OF  CASES   
( N = 60)  
PERCENTAGE  
FEVER  20  38%  
VOMITING  10  17%  
INCREASE  IN  HEAD    
CIRCUMFERENCE  
9  15%  
ALTERED  
SENSORIUM  
5  10%  
SEIZURES  5  10%  
VISUAL    
DISTURBANCES  
4  5%  
SHUNT  TRACT  
INFLAMATION  
3  5%  
  
 Fever  is  present  in  38%   of  cases , followed  by  vomiting(17%)    and increase   
in      head  circumference( 15%).  
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TABLE 4-  COMPARISON  OF  DURATION  OF  INFECTION   AND   
RISK  OF  INFECTION (n=60)  
DURATION  OF  INFECTION  
NUMBER  
OF   
CASES  
( N =  60 )  
RISK   OF   
INFECTION  
SSI-  MEN  
SURGICAL  SITE  INFECTION  
(MENINGITIS 
&ENCEPHALITIS)  
(within  90  days  of  shunt  
insertion  
55  92%  
CNS  -MEN  
CENTRAL  NERVOUS  
SYSTEM  - 
(MENINGITIS & 
ENCEPHALITIS)  
(after  90  days  of  shunt  
insertion)  
5  8%  
    
SSI-MEN  which  includes  surgical  site  infection  with  signs  of  both  
meningitis  and   encephalitis  within  ninety  days  of  shunt  surgery   has   highest   
infection  rate  (92%)  rather than CNS - MEN case.  
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TABLE 5:  INDICATIONS  FOR  VENTRICULOPERITONEAL SHUNT   
SURGERY (n=60)  
Indications for VP shunt  
  
surgery  
No of Cases  Percentage  
Obstructive  
hydrocephalus(n=18)  
18  30.0  
Myelomeningocele with multiple    
revision (MMC-MR)(n=14)  
  
14  23.3  
Preterm with intraventricular    
hemorrhage(Preterm with 
IVH)(n=10)  
10  16.7  
Hydrocephalus following space    
occupying lesion (H-
SOL)(n=5)  
5  8.3  
Post tuberculosis meningitis (Post 
– TBM)(n=5)  
5  8.3  
Post  traumatic hydrocephalus 
(Post Traumatic H )(n=3)  
3  5.0  
Sporadic hydrocephalus    
(SH)(n=5)  
5  8.3  
Total  60  100.0  
  
Association  between  the  indicators  of  ventriculoperitoneal  shunt  surgery  
and  outcome  of   patient  has  been  analysed  and  statistically   significant   P   
value  obtained.  Better  outcome  of   survival  noted  in  obstructive  hydrocephalus   
patients with ‘P’ value 0.016.   Preterm with intraventricularhemorrhage (Preterm 
with IVH) is associated with a significant ‘P’ value  <0.016.  
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TABLE  6: REVISIONS  ASSOCIATED  WITH  DIFFERENT   
INDICATIONS  OF  VENTRICULOPERITONEAL  SHUNT  
SURGERY (n=10)  
  
EARLY INFECTION (80%)  LATE INFECTION (20%)  
INDICATIONS  
No of 
cases  
INDICATIONS  No of cases  
POST TUBERCULOUS 
MENINGITIS  
3  OBSTRUCTIVE  
HYDROCEPHALUS  
FOLLOWING  SOL  
1  
MYELOMENINGOCOELE  2  SPORADIC  
HYDROCEPHALUS   
FOLLOWING  SOL  
1  
PRETERM BIRTH WITH  
INTRA VENTRICULAR 
HEMORRHAGE  
1    
OBSTRUCTIVE  
HYDROCEPHALUS  
1  
HYDROCEPHALUS  
FOLLOWING SPACE  
OCCUPYING LESIONS  
1  
Revision  surgery  is  increased  in  post  tuberculous  meningitis  (37.5%)  
when  compared  to    hydrocephalus  following  birth  defects,  and  posterior  
cerebellar  tumours. Among  hydrocephalus  following  birth  defects, 
myelomenigocele  is  associated  with  multiple  revisions.  
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TABLE 7: PATHOGENS ISOLATED  IN VP SHUNT INFECTION (n=10)  
  Isolate  Frequency  Percentage  
Gram Positive  
Organism  
CoNS  
1 Methicillin sensitive (5)  
2 Methicillin resistance (0)  
5  50  
Staph aureus  
  
 
MRSA  (1)  
Methicillin resistance  
1  10  
Gram Negative  
Organism  
E.coli  
2  20  
   
 Acinetobacter  1  10  
Pseudomonas  
1  10  
  Total  10  100  
    
From total 10 isolates 6 isolates were Gram positive organism and 4 isolates 
were Gram negative organism.  
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TABLE  8: DISTRIBUTION  OF GRAM POSITIVE COCCI IN VP  
SHUNT INFECTION  
Gram Positive Cocci  No of Cases  Percentage  
S.epidermidis  3  50%  
S.hemolyticus  1  16.66%  
S.lugdunensis  1  16.66%  
S.aureus  1  16.68%  
 
 CoNS  has  higher  percentage of infection  around  83.32%  when compared to 
Staph aureus  around  16.68%.  
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TABLE 9: ANTIBIOTIC SUSCEPTIBILITY PATTERN OF GRAM  
POSITIVE COCCI  
     
 
  
CoNS 
n=5  
5 
(100%)  
5 
(100%)  
5 
(100%)  
R  
4 
(80%)  
4 
(80%)  
5 
(100%)  
Staph aureus 
n=1  
R  R  
1 
(100%)  
R  R  
1 
(100%)  
1 
(100%)  
  
All the 5 isolates of CoNS were sensitive to Pencillin, Cefoxitin, 
Teicoplanin  and  Ampicillin.  4  isolates  were  sensitive  to  Cotrimoxazole.  All 
the  5  isolates  of  CoNS  were  resistant  to  Gentamycin.  
Single  isolate of Staph aureus was 100% sensitive to Teicoplanin, and 
Linezolid,  wheras  it  was resistant to Pencillin, Cefoxitin, Gentamicin and  
Cotrimoxazole.  
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TABLE 11:  DETECTION  OF MINIMUM INHIBITORY  
CONCENTRATION BY E-STRIP FOR  
STAPHYLOCOCCUS  
S.No  DRUGS  MIC μg/ml   
Observation   Inference   percentage  
1  Vancomycin for  
Staph aureus  (1)  
≤ 2  sensitive    17%  
2  Vancomycin for  
CoNS (5)  
≤ 4  sensitive  83 %  
  
All the isolates were sensitive to Vancomycin.  
  
TABLE 12  DETECTION  OF MINIMUM INHIBITORY  
CONCENTRATION BY E-STRIP FOR 
ACINETOBACTER  
  
S.No  DRUGS  CONCENTRATION OF  
DRUGS  
S / R  
1  Meropenem  0.0002-32μg/ml  R  
2  Colistin  0.016-32 μg/ml  S 0.094 
μg/ml  
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TABLE 13: DETECTION OF ESBL PRODUCTION AMONG GRAM 
NEGATIVE BACILLI BY VARIOUS METHODS.  
S.No  TEST METHOD (n=2)  ESBL DETECTION  
1  Screening Method (Standard Disc 
diffusion) Positive (2)  
100%  
2  Confirmatory Test (Standard Disc  
Diffusion) Positive (2)  
50%  
3  E-Strip Method (2)  100%  
  
  Two isolates of E.coli were Extended Spectrum Beta Lactamase producers 
which was identified  by screening method and confirmed by standard disc 
diffusion method  and  E-strip method.  
Single  isolate of  acinetobacter  was  screened  with Cefoxitin disc  for  
Metalo Beta Lactamase  production  and  confirmed  with disc diffusion and       
E-strip method   but  molecular  identification  is   confirmatory.  
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TABLE 14: ASSOCIATION OF OUTCOME WITH RISK  FACTORS  
Association of Outcome with 
Indication of VP shunt  
Outcome  
Survival  
Rate  
Mortality-
Rate  
 Obstructive hydrocephalus 
(Obstructive) (18)  
18  0  
Myelomeningocele with multiple 
revision (MMC-MR)(14)  
12  2  
Preterm with    
intraventricularhemorrhage(Preterm 
with IVH) (10)  
4  6  
Hydrocephalus following space    
occupying lesion (H-
SOL) (5)  
4  1  
Post tuberculosis meningitis (Post 
– TBM)(5)  
5  0  
Post  traumatic hydrocephalus (3) 
(Post Traumatic H )  
2  1  
Sporadic (5)hydrocephalus (SH)  
4  1  
Total  
49  11  
  
Survival rate after VP shunt surgery is increased in  Obstructive 
hydrocephalus  and   Mortality  rate  is  increased   Preterm with intraventricular 
hemorrhage.  
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TABLE 15: OUTCOME OF PATIENTS WITH THE  ISOLATED  
PATHOGEN  IN VENTRICULOPERITONEAL  SHUNT   
INFECTION  
S.No  Organism  Survival  Mortality  
 Rate  
Survival   
%  
Mortality  
%  
1  Gram Positive  
Cocci (6)  
4  2  66.66  33.34  
2  Gram Negative  
Bacilli (4)  
1  3  25  75  
  
 Survival  rate  is  increased  in  infection  with  Gram  positive  organism and it 
is drastically decreased in case of Gram negative organism like Acinetobacter,  
Pseudomonas  and  E.coli.    
    
CHART  1: DISTRIBUTION OF  CASES  WITH VP SHUNT 
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CHART -3 :   CLINICAL  FEATURES   SUGGESTIVE   OF   
VENTRICULOPERITONEAL    SHUNT   INFECTION 
 
 
 
 
CHART 4: DURATION OF INFECTION 
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 CHART 5: INDICATIONS OF VP SHUNT INFECTION 
 
 
CHART 6   : PERCENTAGE   OF   REVISIONS IN EARLY AND LATE 
INFECTION (n=10) 
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CHART 8 : DISTRIBUTION OF GRAM POSITIVE COCCI IN VP SHUNT 
INFECTION  (n=6) 
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CHART  11-   DETECTION  OF  ESBL  BY  DIFFERENT  METHODS 
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DISCUSSION 
Ventriculoperitoneal  shunt  surgery  is  the  most  common  treatment   
modality  for   the  diagnostic  indications  of  hydrocephalus. This  surgery  
enables  drainage  of  excess  cerebrospinal  fluid  from  lateral  ventricles  into  
the  peritoneal  cavity. Shunt  infections  is  one  of  the  predictors  associated  
with  significant  morbidity  and  mortality. 
This  study  was  done  to   analyse  risk  factors,  microbial  profile   of 
Ventriculoperitoneal infection,  the  antibiotic  sensitivity  of  the  pathogens  
isolated    and  clinical  outcome  of  Ventriculoperitoneal  shunt  infections  in  
paediatric  patients. 
This  study  includes    clinical  samples   from  60 paediatric   patients 
following  Ventriculoperitoneal  shunt  surgery. 10  (16.66%)  of  the  cases   
were  culture  positive  and  50   (83.34%)    cases   were   culture  negative.  
The  incidence  rate  in  this  study  is  16.6%.  The  incidence  of  infection  was  
in  concordance  with  the  study  of  Anna Conen et  al,  where  incidence rate  
is  (1 % to 18%).    and   study   by  Xing  Wu et al76,  where  incidence  rate  is  
from  (2 % to   39%).   A  study  by   Dharmajaya  et  al21  showed   the rate  of  
infection to  be  5%    in  Haji  Adam  Malik  Hospital  (Reference  centre  for  
VP  shunt  surgery, North  Sumalda) in contrast.  This  hospital  documented  
the  fact  that  low-levels  of  preoperative  albumin  was  a  significant  factor  
in  increasing  the  infection.  Use  of  antibiotic  impregnated  shunts  in  referral  
centre  leads  to  decline  in  infection  rate. 
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In  this   study,  male  population   constituted   57%  and  females  
constituted  43%.  Gender  distribution  was not of much  significance  except  
for  a  slight  male  preponderance.  This  is  supported   by  a  study  conducted  
by  Vikas  Kumar  et  al71  at  G.B .Pant   Post  Graduate  Institute   where  64%  
of  Ventriculoperitoneal   shunt  surgery  was  done  in  males. This  gender  
dimorphism  is  due  to  hormonal  changes  and  inbuilt  susceptibility  to  
infections  in  male  population.    A  study  done  by  Tamara  D and    Simon  
et al66, is  in  contrast   “where  infection  rates  following  CSF   shunt  placement  
across  paediatric  hospitals  in  the  United  States”, showed  an  increased  risk  
of  infection  in  female  sex.  
In  this  study   60  paediatric  patients  are  included,  of  which  29  cases 
(48%) were  reported  to  have  primary  shunt  insertion  at    less  than  one  
year  of  age.  22  patients  (37%)  had  Ventriculoperitoneal  shunt   insertion  
at  age  between  1 to 5 years  and  9  patient (15%)  were  above  5  years.  In  
a  study   conducted  by  Matthew  J  et  al, the  independent  risk  factors  for  
shunt  infection  was  studied  and  significant  P  value  was  obtained.  His  
study   suggested   that  each  decreasing  year  of  patient  age  was  associated  
with  4%  increase  in  the  risk  of  shunt  infection and  insertion  of  a  
Ventriculoperitoneal  shunt   in  a  premature  infant  was  associated  with  five  
fold  increase  in  the  risk  of  infection. This  finding  is  consistent  with    our    
study  where  majority   of   patients  were  < 1 year.  Incidence  is  high in 
premature infants  because  of  following   reasons: 
1)  Immature   immune  system 
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2) Poor  skin  barrier 
3)  Altered   skin  bacterial  density  
4)  Co –morbidity  
 
 CDC  (2018 )  guidelines   defines  shunt  infection  as;  1)  SSI-MEN  
(Surgical  site  infection  which  includes  both  meningitis  and  encephalitis)  
within  ninety  days  of  infection  and  2)  CNS  -MEN  (Central  Nervous  
System  which  includes  both  meningitis  and  encephalitis)  after  ninety  days  
of  infection.  In  this  study  55  cases  (92%)  of  cases  where  reported  as  
SSI-MEN and  5  cases  (8%)  were  reported  as  CNS- MEN.  In  a  study  
conducted  by  Wellingson  Silva  et  al74, 90%  of  VPS  infections  were  
identified  at  first  three  months,  this  reinforces  the  fact  that  these  infections  
are  a  result  of  skin  commensals  at  the  surgical  site  in  Gram  Positive  
Cocci   infections   and   retrograde  infections  from  bowel  in  case  of  Gram  
Negative  infections.  
In  this  study,  clinical  features   of  patients  were  analysed. Fever   
(38%), vomiting (17%), increase in head circumference in 15%, altered  
sensorium (8%), seizures (8%), visual disturbance (6%) and shunt tract  
inflammation  was  noted  in  5%.  In  a   study  conducted  by  Mwang  Ombe  
et  al   similar  clinical  features  were  noted  of  which  fever, irritability   and  
vomiting  were  the  most  common  features.  Abdominal  distension  was  also 
noted  in  few  of  the  paediatric  patients. 
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The  etiology  of  hydrocephalus  in  paediatric  age  group  who  required 
shunt surgery were; 1)  congenital malformations  (Myelomeningocele  23%  
and  Obstructive  Hydrocephalus  30%),  2) Gestational  defects  17% (Preterm  
with  Intra Ventricular  Hemorrhage),  3) hydrocephalus  following   tuberculous  
meningitis 8.3%,  4) trauma  (5%),  5) posterior  cerebellar  fossa  tumours  
(8.3%)  and  6) sporadic  causes(8.3%).   
In  a  study  conducted  by  Tamara  D  Simon et  al66,  the  following  
indications  for  CSF  shunt  placement  was  documented,  Myelomeningocele  
(21%),  IVH  (15%),  Aqueductal  stenosis  (12% ).  The  percentage  in  
Obstructive  causes   and   IVH  are   increased   in  this   study,  which   indicates   
that   Anti –natal  screening   program  must  be  improved  with  intake  of   
folic  acid   to  prevent  neurological  complications. 
In  this  study,  statistically  significant  P  value   has  been  obtained  for  
two  independent  risk  factors.  For   Obstructive  hydrocephalus 0.016    and   
0.001  for  Preterm   with   IVH.  In   a  study   conducted  by  Matthew  J. 
McGirt46,  the  P  value  for  premature  birth  is  0.0002 which is similar to this 
study.  This could be   attributed  to  poorly  developed  immune  system  and  
the  high  density  of  bacteria  on  premature  skin. 
In  this  study following  VP shunt  surgery ,symptomatic    cases  of 
infection  were  60 .Out  of  which  48   cases   had   primary  
Ventriculoperitoneal  shunt  surgery and  12  cases   underwent     Revisions.  . 
Revision   shunt  surgeries  were   increased   in   hydrocephalus  following   
tuberculosis  meningitis (38%)   and  Myelomeningocele (25%).   A  study   
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conducted  by  Vikas  Kumar  in  Neurosurgical  unit  for  a  period   of  six  
years   included  1186  VP  shunt  surgeries71.  259 (21.8%)  cases  underwent  
shunt  revisions  with  83  cases  (24%) of  tuberculous   meningitis    as  a   
leading  etiology  for  revision  surgery.  Poor  general  conditions  of  the  patient   
and  high  cellular  content  of  CSF  are  the  important  reasons  for  revisions  
in tuberculous Ventriculoperitoneal  surgery . 
Incidence   of   Ventriculoperitoneal   shunt   infection   varies    from   
(3  -  13 % ),  in   the  Western  world  and  in  United  Kingdom  5.2%  infection  
rate  was documented. In this study,  the  incidence rate  was  17 %  with 60 % 
of   infection  caused   by  Gram   Positive  Cocci   and 40 %  of   infections  
caused  by  Gram Negative  Bacilli .After  speciation  of  Gram  Positive  Cocci,  
it  was  found that  CoNS  showed  a higher percentage of infection around 
83.32% when  compared  to  Staph  aureus  (16.68%).In  a  study  done  by  
Sarguna  et  al61,  Shunt  associated   infections(65%)  are  caused  by  Coagulase  
Negative  Staphylococcus (CoNS)  and  19  to  22%  of  infections  were  caused  
by  Gram  Negative  Bacilli. 
CoNS  (65%)  was  the  most  common  organism  causing  VP  shunt  
infection .  This  study  is  in  concordance  with  Sarguna  et al  study61. Among  
5  isolates  of  CoNS,  3  isolates  were  S.epidermidis  and  1  isolate  of  
S.hemolyticus  which  hydrolysed  urea  was  documented.  Single   isolate  of  
S.lugdunensis  which  produces  clumping  factor  is  negative  for  tube  
coagulase  and  DNase  test.  S.lugdunensis  is  an  emerging  pathogen  in  VP  
shunt  infections.  In  a  study  by  J.A.T  Sandoe  and  Longshow,  50%  of  VP  
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shunt  infections  were  caused  by  CoNS,  due  to  its  affinity  to  adhere  to  
plastics.  The  above  study  suggest  that  CoNS  are  low  virulence  pathogens  
but  S.lugdunensis  are  aggressive  organisms  with  tendency  to  cause  
opportunistic  infection.  CoNS  infections  are  indolent  and  subacute  in  
presentation,  with  a  tendency  to  form  biofilm.  Treatment  involves  removal  
of  shunt  with  administration  of  intrathechal  antibiotics. 
CoNS  infections   are   associated  with  biofilm  formation  when  plastic  
indwelling  devices  are  placed  in  sterile  sites.  The   characteristic  feature  
of  biofilm  formation  is  initiated  by  adherence   and  proliferation   of the 
organism due to virulence  factor  coded   by  PSM  genes. Phenol  Soluble  
Modulins   leads  to  maturation of the biofilm,  detachment  and   sepsis.  
All the 5 isolates of CoNS were sensitive to Pencillin,  Cefoxitin, 
Teicoplanin  and  Vancomycin. 4  isolates  were  sensitive  to  Cotrimoxazole 
and 3  isolates  were  sensitive  to Ciprofloxacin.  All  the 5 isolates  of  CoNS 
were  resistant  to  Gentamicin . 
One isolate  of  Staph aureus  was  100%  sensitive to Teicoplanin, 
Linezolid,  Vancomycin whereas it   was resistant to Pencillin, Cefoxitin, 
Gentamycin, Ciprofloxacin and Cotrimoxazole.  Minimum  Inhibitory  
Concentration  (MIC)  of   Vancomycin  by  E-strip  for  Staph aureus  and 
CoNS  was  done  and  all  the  6  isolates  were  100%  sensitive  to  Vancomycin. 
 All the two isolates  of  E.coli  were ESBL  producers  with  resistance  
to Ampicillin,  Ceftazidime,  Cefotaxime,  Netilimycin  and  Gentamicin.  It  
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was sensitive  to  Cefoxitin,  Cefoperazone sulbactan,  Levofloxacin,  
Tigecycline, Meropenem,  Aztreonam  and  Piperacillin  &  tazobactam. 
 The single isolate  of  Pseudomonas  was   sensitive  to  Ceftazidime, 
Cefoperazone sulbactan,  Netilimycin,  Levofloxacin, Tigecycline, 
Meropenum,  Aztreonam  and  Piperacillin  &  tazobactam.  It  was  resistant  to 
Ampicillin,  Cefoxitin,  Cefotaxime,  and  Gentamicin.  Blood  culture  was  also 
positive  for  Pseudomonas  in  this  patient  and  the  patient  died of  
septicaemia. 
 Acinetobacter baumanii ,single  isolate was sensitive to Netilimycin, 
Levofloxacin, and Tigecycline . It was resistant to all cephalosporins, 
carbapenems  and  Monobactam.  The  patient  is  a  5 year  old  boy  who  
underwent  repeated  revisions  following  meningioma  of  sphenoid  wing.  
The  acinetobacter  isolated  was  a  Metallo  Beta  Lactamase  producer,  which  
was  screened  and  confirmed  by  Disk  diffusion  (Imipenem  and  Imipenem  
with  EDTA).  Further  confirmation  with  E-strip  (Meropenem  with  and  
without  EDTA)  was  done. However   the  patient  succumbed     following 
third  revision.  
 Survival  rate  is  increased  in  infection  with  Gram  Positive  Cocci  
67%  and  it  is  drastically  decreased  in  case  of  Gram  Negative  Bacilli   
25%  (E.coli,  Acinetobacter,  and  Pseudomonas). 
 Follow up  of  the  60  patients  who  underwent  Ventriculo peritoneal  
shunt  surgery  was  done  of  which  47  cases  survived with  better  neurological  
outcome.  11  patients  died  and  2  patients  had  shunt  malfunction. 
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Though  the  treatment  is  mostly  shunt  removal  followed  by 
temporary  CSF  divergence  with  EVD,  the  duration  of antibiotic therapy 
and the length of time during which the shunt is exteriorised is of much 
significance.  This is especially so with MDR pathogens and may lead to  
complications like recurrence, revision, meningitis,  ventriculitis and 
encephalitis  leading  to  increased  mortality.  Loss  of  IQ  with  increased  risk 
of  seizures  due  to  neuronal  death. 
Of  late  antibiotic  impregnated  shunts  with  Rifampicin/Clindamycin 
are  used  which  kill  the  bacteria  rather  than  preventing  adherence.  EVD 
with  silver  impregnated  drains  have  also  come  into  vogue  and  these  in  
turn   prevent initial adherence of organisms.  Hydrogels which reduce 
microbial  viability  without  causing  cytotoxicity have been advocated 
recently. 
Prevention is by following  institutional  standardized  protocols  hand 
washing,  double  gloving,  decreasing  bacterial load of patient's skin, minimal  
shunt  handling  and  peri-operative  antibiotics  where  Microbiology  plays  a  
significant  role. 
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SUMMARY 
 
 This  study  was  done  for  a  period  of  18  months  involving  60  
paediatric  patients  of  both  gender  and  age  group  below  13  years. 
 VP  Shunt  surgery  was  done  in  48  patients  and  about  12  patients  
had  undergone  VP  shunt  revisions. 
 10  patients  were  infected  giving  an  infection  rate  of  16.6%. 
 The  study  included  57%  males  and  43%  of  females. 
 Diagnostic  indication  for  hydrocephalus  necessitating  shunt  surgery  
were;  1)  Congenital  malformations  (53%),  2)  preterm  and  IVH  
(17%),  3)  Hydrocephalus following  tuberculous  meningitis  (8.3%),  
4)  trauma  (5%),  5)  Posterior  cerebellar  fossa  tumours  (8.3%),  6)  
Sporadic  cases  (8.3%). 
 The  clinical  features  of  patients  with  shunt  malfunction  included  
fever,  vomiting,  increase  in  head  circumference,  altered  sensorium,  
seizures,  visual  disturbances  and  shunt  tract  inflammation. 
 Majority  of  shunt  infections  occurred  within  a  period  of  90    days  
of  shunt  infection  (92%)  and  most  of  infections  occured in  age  
group  of  less  than  one  year (48%). 
 In  this  age  group  (<1 year)    obstructive  hydrocephalus  and  preterm  
with  IVH  were  found  to  be  significant  risk  factors. 
 VP  shunt  surgery  improved  the  survival  rate  of  patients  with  
obstructive  hydrocephalus. 
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 Revision  surgery  is  significantly  increased  in  post  tuberculous  
meningitis  (37.5%)  when  compared  to  hydrocephalus  following  birth  
defects  and  posterior  cerebellar  tumours. 
 The  common  pathogen  isolated  was  CoNS  (83%),  and  other  
pathogens  are  staphylococcus  aureus  (16.68%),  E.coli  (20%),  
Acinetobacter  (10%)  and  pseudomonas  (10%). 
 Gram  Positive  cocci  were  100%  sensitive  to  Vancomycin  and  
sensitivity  of  Vancomycin  by  E-strips  for  S.aureus  was  less  than  2  
mg/ml  and  for  CoNS  it  was  less  than  4mg/ml. 
 Both  MIC and Disc  diffusion  methods  demonstrated  resistance  to  
Meropenem.  The  MIC  for  colistin  was  done  and  it  was  sensitive. 
 Among  Gram  Negative  Bacteria,  ESBL  accounted  for  50%,  and  
MBL  for  25%,  pseudomonas  was  100%  sensitive  to  ceftazidime  
and  Piperacillin  with  Tazobactam. 
 Emergence  of  MDR isolates have necessitated  molecular  diagnostics 
such  as  PCR  which enhance rapid  identification  of  shunt infected  
pathogens. 
 Treatment  protocol  followed  was  shunt  removal,  intravenous  
antibiotic  therapy  and  shunt  reinsertion  was  done  after  seven    days  
in  CoNS  infection,  in  case  of  GNB  infection  antibiotics  was  
extended  upto  14  to  21  days  with  extraventricular  drain. 
 Survival  rate  was increased  in  Gram  Positive  Cocci  infections  (67%)  
when  compared  to  Gram  Negative  Bacilli  infections.  
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CONCLUSION 
 Ventriculoperitoneal shunt infection is one of the major complications 
associated with mortality and morbidity resulting in neurological 
disturbances. 
 The infection rate in patients with ventriculoperitoneal shunt was  
16.66%. 
 A large number of infections occurred in children with congenital 
malformations and preterm with intraventricular hemorrage. 
 Most of the infections occurred within three months of surgery. 
 Staphylococcus epidermidis was the commonest pathogen isolated  and  
survival  rate  is  more  in  gram positive  infections. 
 Promising results are obtained by early removal of the shunt hardware 
accompanied by appropriate antibiotic therapy until CSF culture turns 
negative, followed by shunt replacement. 
 With the emergence of methicillin resistant strains, ESBL and MBL 
producers, diligent use of antibiotics will restrict the spread of drug 
resistant strains in the community and environment.  Determining  MIC 
with E-strips are  extremely  useful  in  these  cases  and  will  go  a  long  
way  if   implemented in routine use. 
 Infection Control Committee at the Institutional level plays a significant 
role in framing antibiotic policy and standardization of protocol to be 
followed in such infections thus limiting the spread of these drug 
resistant nosocomial pathogens. 
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ANNEXURES 
PROFORMA 
 
Name : 
Age : 
Sex : 
Address : 
 
 
History of Preterm Birth   : 
History of Repeated Shunt Surgery :   
Complaints of Fever  : 
Complaints of Vomiting : 
Complaints of Neck Stiffness : 
Complaints of persistent cry : 
Complaints of poor feeding  : 
Signs suggestive of Ascites : 
Signs suggestive of Neuromotor Deficit : 
 
STATEMENT OF CONSENT 
 
 I, …………………………………….., do hereby volunteer and consent to 
participate in this study being conducted by Dr. M. Sangeetha, I have read and 
understood the consent form (or) it has been read and explained to me thoroughly. 
I am fully aware of the study details as well as aware that I may ask questions to 
her at any time. 
 
 
Signature / Left Thumb Impression of the Patient 
Station: Coimbatore 
Date: 
 
 
Signature / Left Thumb Impression and name of the witness 
Station: Coimbatore 
Date: 
STATEMENT OF CONSENT 
I, _____________________, do hereby volunteer and consent to 
participate in this study being conducted by Dr.M.Sangeetha , I have read 
and understood the consent form (or) it has been read and explained to me 
thoroughly. I am fully aware of the study details as well as aware that I 
may ask questions to him at any time. 
 
 
Signature / Left Thumb Impression of the patient  
Station: Coimbatore 
Date: 
 
 
Signature / Left Thumb Impressionand Name of the witness  
    
Station: Coimbatore 
Date: 
 
 
 
 
 
 
 
 
ஒப்புதல் படிவம் 
பெயர் ……………………………………………………………………………………..  வயது ………………………………………..  
முகவரி ……………………………………………………………………………………………………………………………………………………………..  
ஆகிய நான் நுண்ணுயிரியல் துறை மருத்துவக் கல்லூரி ெட்ட 
மமற்ெடிப்பு மாணவி மரு. சங்கீதா. ம  அவர்கள்   குழந்றதகளுக்கான 
பவன்ட்ரிபெரிமடானியல் புை பதாற்று கிரிமிகள்   என்ை தறைப்ெில் 
பசய்யும் ஆய்வில் என் குழந்றதறய ஆய்வு பசய்ய சம்மதிக்கிமைன். 
இந்த ஆய்வில் பசய்முறை மற்றும் இது பதாடர்ொன அறனத்து 
விளக்கங்கறளயும் மகட்டுக்பகாண்டு எனது சந்மதகங்கறளயும் 
பதளிவுெடுத்தி பகாண்மடன் என்ெறதயும் பதரிவித்துக்பகாள்கிமைன். 
இந்த ஆய்வில் என் குழந்றதறய உட்ெடுத்த முழு மனதாக சுய 
சிந்தறனயுடன் ஒத்துக்பகாள்வதுடன் எந்த மநரத்திலும் இந்த ஆய்வில் 
இருந்து விைகிட எனக்கு உரிறம உண்டு என்ெறதயும் அைிமவன்.  
இந்த ஆய்வில் என் குழந்றதயின்.விவரங்கள் ொதுகாக்கப்ெடுவதுடன் 
இதன் முடிவுகள் ஆய்விதழில் பவளியிடப்ெடுவதில் ஆட்மசெறன 
இல்றை என்ெறத பதரிவித்துக்பகாள்கிமைன். 
இடம்: 
மததி: 
றகபயாப்ெம் றகமரறக 
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04.01.201
8
B/0 N
eelam
egam
+
M
M
C , M
R
D40
PO
D 10 Day N
G
2.12.18 N
G
4.1.18 
Pale of 
Sam
ple 
Collector
D50
2.12.18
4.1.18 
Date of 
Sam
ple
D50
2/12/2018
4.1.18 
Date of 
Sam
ple
P
_
-
Few
 
Pus
Few
 GN
B
N
G
N
G
N
G
N
IL
N
G





N
G
Alive /GC 
29
M
-100 
04.11.18
Bhavani Picu case
+
Post 
Traum
atu 
hrdrocephe
9Yrs
PO
D 7 Day
-
-
PO
D 7 Day
_
-
P
Few
 
Pus
Few
 GN
B
N
G
-
N
G
N
IL
N
G





N
G
Alive /GC 
30
M
-102 
04.01.201
8
B/o Krishnaveni
+
M
M
C , M
R
D40
PO
D 10 Day N
G
2 M
onth N
G
4 M
onth 
4.1.18
-
-
Shunt 
rem
oved 
04.1.18
N
G
N
G
Current 
Sam
ple 
Collection 
4.1.18
_
-
P
Few
 
Pus
Few
 GPC
W
hite O
paque 
Colony
W
hite 
O
paque 
Colony
W
hite O
paque 
Colony
Coagulase (P) 
M
od .O
X (P)   
HU
GH LEIFSO
N
 
oxidative
N
G





CoN
S
VAN
, AM
C 
B-(s), FZ-(R)
_
CO
T, 
LZ,CFS,CIP, 
AM
P AK
Alive /GC 
31
M
-169 
07/01/201
8
B/o M
ehitha
+
M
M
C , M
R
D40
PO
D 5Day N
G
DO
S      2/12 
M
onth 
7.1.18
-
IN
TACT
DO
S  7.1.18
-
45 Days N
G
DO
S  7.1.18   
-
P
-
-
Few
 
Pus
Few
 GPC
W
hite O
paque 
Colony
W
hite 
O
paque 
Colony
W
hite O
paque 
Colony
Coagulase (P) 
M
od .O
X (P)   
HU
GH LEIFSO
N
 
oxidative
N
G





CoN
S
VAN
, B-(s), 
FZ-(R)
-
AM
C,CO
T, 
LZ,CFS,CIP, 
AM
P AK
Alive /GC 

reshinted after 1 w
k
32
M
-776 
31.01.201
8
B/o Vedhapriya
+
Preterm
 IVH
D40
PO
D 2
-
-
31/1/18
-
-
P
-
-
M
any
-
N
G
N
G
N
G
N
IL
N
G





N
G
Dead D42
33
M
-796 31-
1-2018
B/o M
ahesw
ari
+
Preterm
 IVH
D40
PO
D 5
-
-
31/1/18
-
-
P
-
-
M
any
-
N
G
N
G
N
G
N
IL
N
G





N
G
Dead D50
34
M
-1163 
14.02.201
8
Ashw
in
+

D30
PO
D 10 Day N
G
2 m
onth 
14.2.18
-
-
shunt 
14.2.18
-
-
Blood 
14/2/18
-
P
-
-
M
any
Few
 GPC 
Seen
W
hite O
paque 
Colony
W
hite 
O
paque 
Colony
W
hite O
paque 
Colony
Coagulase (P) 
M
od .O
X (P)   
HU
GH LEIFSO
N
 
oxidative
N
G





CoN
S
VAN
, B-(s), 
FZ-(R)
-
AM
C,CO
T, 
LZ,CFS,CIP, 
AM
P AK
Alive /GC 
35
M
-1236 
17.02.201
8
B/o Saranya kannan
+
Preterm
 IVH
3 m
onth
15 Days after surg 
17.2.18
-
-
Shunt 
17.2.18
-
-
Blood 
17.2.18
-
-
P
-
-
Few
N
O
N
G
N
G
N
G
N
IL
N
G





N
G
-
-
Alive /GC 
36
M
-1549 
28.02.201
8
B/o Sakitha
+
PRETERM
D35
PO
D 2 28/2
-
-
Shunt 28/2
-
-
Blood 28/2
-
-
P
-
-
M
any
Few
 GPC 
in Cluster
W
hite O
paque 
Colony
W
hite 
O
paque 
Colony
W
hite O
paque 
Colony
Coagulase (P) 
M
od .O
X (N
)   
HU
GH LEIFSO
N
 
ferm
entative
N
G





staph aureus
VAN
, B-(R), 
FZ-(S)
AM
C,CO
T, 
LZ,CFS,CIP, 
AM
P AK
Dead 2 PO
D
37
M
-1633 
03.03.201
8
Lakshm
i Krishnan
+
PO
ST 
TRAU
M
ATC 
HYDRO
CEP
7yrs
10th PO
D  3.3.18
-
-
-
-
-
Blood 3.3.18
-
-
P
-
-
M
any
N
o 
N
G
N
G
N
G
N
IL
N
G





N
G
Alive /GC 
38
M
-1814 
10.3.2018
Raghhasudha Traum
a 
w
ard
+
Post 
Traum
atu 
hrdrocephe
91/2 yrs
15th PO
D  10.3.18
-
-
Shunt 
10.3.18
-
-
Blood 
10.3.18
-
-
P
-
-
M
any 
Pus
N
o 
N
G
N
G
N
G
N
IL
N
G





N
G
Dead
39
M
-1824 
10.3.2018
B/o valli
+

21/2 M
onths
15th PO
D  10.3.18
-
-
Shunt 
10.3.18
-
-
Blood 
10.3.18
-
-
P
-
-
Few
-
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
40
M
-1825 
10.3.2018
B/o Deepa
+

2 m
onth
5th PO
D 10.3.18 
-
Blood 
10.3.18
-
-
P
-
-
Few
-
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
41
M
-1967 
15.3.18
Sunil Kum
ari
+
H-SO
L  
astrocylom
a
7.1.18 SO
L Excis 
28.2.18 VP 
Shunt Inse
D17 Infection 
15/3/18
-
-
D17 15.3.18
-
-
D17 15.3.18
-
-
P
-
-
P
-
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
42
M
-2007 
17.3.18
Jais N
i
+
Sporadic 
Hydrocephe
tes
13/4 age 7.1.18
2 m
onth 17..18
-
-
17.3.18
-
-
P
-
-
-
-
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
43
M
-2627 
17.3.18
B/o Abim
anya
+

2 m
onth
20th PO
D  17.3.18
-
-
PO
D 20 
17.3.18
-
-
PO
D 20 
17.3.18
-
-
P
-
-
-
-
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
44
M
-2780 
23.3.18
B/o Kavi M
ozhi
+

3 m
onth
10th PO
D  23.3.18
9/5/18 M
-
3259
23.3.18
9/5/18 M
-
3059
-
P
-
-
-
P
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
45
M
-2627 
11.4.18
Aishw
arya
+

10 m
onth 
19.2.18
After 2 m
onth 
11.4.18
-
-
19.2.18
-
-
P
-
-
P
-
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
46
M
-3340 
13.5.18
B/o Saranya
+
M
M
C, M
R
2 m
onth
15th PO
D  13.5.18 N
G
8/7/2018
-
13.5.18
8/7/2018
-
13.5.18
8/7/2018
-
P
-
-
-
P
N
G
N
G
N
G
-
N
G





N
G
47
M
-4025 
9.6.18
B/o Revathi
+
M
M
C, M
R
21/2 M
onths
15th PO
D  9.6.18
10/8/2018
-
PO
D 15 
9.6.18
10/8/2018
-
PO
D 15 
9.6.18
10/8/2018
-
P
-
-
-
P
N
G
N
G
N
G
-
N
G





N
G
48
M
-4308 
12.6.18
Sum
ardha
+
H-SO
L
1 m
onth Prior 
SO
L rem
oved VP 
Shunt Intrusion
18th PO
D 20.6.18
-
-
PO
D 
18.20.6.18
-
-
13.5.18
-
-
P
-
-
FEW
 
FEW
 GPC 
CLU
STER
S  
W
hite O
paque 
Colony
W
hite 
O
paque 
Colony
W
hite O
paque 
Colony
Coagulase (P) 
M
od .O
X (P)   
HU
GH LEIFSO
N
 
oxidative
N
G





CoN
S
VAN
, B-(s), 
FZ-(R)
-
AM
C,CO
T, 
LZ,CFS,CIP, 
AM
P AK
Alive /GC 
49
M
-4310 
12.6.18
Balaji
+
H-SO
L 
Astrocycle
1 m
onth Prior 
SO
L rem
oved VP 
Shunt Intrusion
20th PO
D 20.6.18
D
O
S      2/12 
M
onth 
7.1.18
P
PO
D 20 
20.6.18
-
-
PO
D 20 
20.6.18
-
_
L_
-
-
-
N
G
N
G
N
G
N
G





N
G
Alive /GC 
50
M
-4435 
12.6.18
Dyan Yadhan
+
M
M
C, M
R
D40
D15 25.6.18
-
-
25.6.18
-
-
25.6.18
-
-
P
_
-
-
-
N
G
N
G
N
G
-
N
G





N
G
Alive /GC 
51
M
-5201 
18.6.18
B/o M
asilam
ani
+
P
D40
D5 25.6.18
-
-
D5 25.6.18
-
-
D5 25.6.18
-
-
P
__
_
-
-
N
G
N
G
N
G
-
N
G





N
G
Dead
52
M
-6054 
18.6.18
Angel
+
Sporatic H
5 m
onth/ FCH
9 m
onths   29.6.18
P
P
9 m
onths  
29.6.18
-
-
9 m
onths 
29.6.18
-
_
L
_
FEW
FEW
 GN
B
N
LF/GW
C
N
LF/GW
C
N
LF/GW
C
O
X &
Citrate (P) 
TSI - K/N
C 
N
G





pseudom
onas
M
RP,PIT, 
CFS
     Am
p,CIP,LE,AK,G 
2.7.18 pt died due to 
septicem
ia
53
M
-6056 
18.6.18
Asw
ini Pandi
+
P
D40
10th PO
D  29.6.18
10thPO
D  
29.6.18
P
10th PO
D  
29.6.18
-
-
10th PO
D  
29.6.18
-
_
P
-
-
-
-
N
G
N
G
N
G
-
N
G





N
G
Dead
54
22.6.18
Akilesh
+
O
5 yrs
P
P
P
P
-
-
-
-
N
G
N
G
N
G
-
N
G





N
G
 
AliveGC

55
26.6.18
B/o. Selvam
ani
+
O
3 m
onths
15th  PO
D
15th  PO
D
15th  PO
D
L
-
-
-
N
G
N
G
N
G
-
N
G





N
G
 
AliveGC

56
26.6.18
Sushm
itha
+
Sporatic H
1m
onth before
30th PO
D
-
-
30th pod
-
-
30th PO
D
-
-
P
-
_
-
-
N
G
N
G
N
G
-
N
G





N
G
 
AliveGC

57
29.6.18
Subiksha
+
Sporatic H
AT  10 m
onth
30 th  PO
D
_
(-)
30th pod
-
_
30th PO
D
_
_
P
-
_
-
-
N
G
N
G
N
G
-
N
G





N
G
 
AliveGC

58
29.6.18
Dhanashree
+
Post TBM
AT  8  m
onth
40th PO
D
P
-
40th PO
D
P
-
2 m
onth 
_
_
-
-
P
Few
 
-
N
G
N
G
N
G
-
N
G





N
G
 
AliveGC

59
29.6.18
Praneeth
+
O
4m
on
O
bst Hydro
6m
on
06/06/17
-
-
6m
on
06/06/17
-
-
6m
on
06/06/17
_
-
-
-
P
-
Few
 GN
B
N
G
N
G
N
G
N
IL
N
G



N

N
G
Alive
GC
60
29.6.18
B/O
 Deivani
+
P
D35
5TH PO
D
06/06/17
-
-
5th PO
D 
6/6/17
-
-
5th PO
D 
6/6/17
-
-
-
-
P
Few
-
N
G
N
G
N
G
N
IL
N
G





N
G
Alive
GC
DO
S:Date of Surgery
M
M
C,M
R:M
yelom
eningocele w
ith m
ultiple revisions
P:Pre term
 w
ith Intraventricular haem
orrhage
CoN
S:
REV:Revision
SO
L-H:Space occupying lesions follow
ed by hydrocephalus
O
:O
bstructive hydrocephalus
PO
D:
no shunt sam
ple
N
o Shunt Sam
ple
  no shunt sam
ple
N
O
 SHU
N
T SAM
PLE
N
O
 SHU
N
T SAM
PLE
N
O
 SHU
N
T SAM
PLE
N
O
 SHU
N
T SAM
PLE
no shunt sam
ple
